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ABSTRACT 
Several of worldwide emerging infections are caused by RNA viruses. For this reason, research in 
the antiviral chemotherapy field is directed toward the development of compounds that target 
various steps of the virus life cycle. In this work the antiviral activity of 5-Acetyl-2-
Arylbenzimidazoles and 2-[(benzotriazol-1/2 yl)methyl]benzimidazoles has been evaluated against 
representatives of several virus families, including HCV BVDV, YFV, REO-1, CVB-5, Sb-1 and 
RSV. Some of the new derivatives turned out to be very interesting for their potency and selectivity 
against BVDV and HCV (the former), and RSV (the latter), and could be promising candidates for 
the treatment of the related diseases. 
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1.0 Global burden of infectious diseases 
Infectious diseases are a leading cause of death worldwide. About 17 million of 57 million annual 
deaths, in a world population of 6.2 billion people, are estimated to be related directly to infectious 
diseases.1 
Actually, poverty, evolving human migration patterns, new infectious agents and changing 
environmental and development activities, all contribute to the expanding impact of infectious 
diseases. Remarkably, 95% of infection-related deaths occur in developing countries. This figure 
does not include the additional millions of deaths occurring as a consequence of complications 
associated with chronic infections.2 In industrialized nations, over the past 100 years life expectancy 
has nearly doubled, and early childhood mortality has fallen 100-fold; notwithstanding, infectious 
disease mortality still disproportionately affects in those countries indigenous and disadvantaged 
minorities.3 
Since the discovery of the deadly Ebola virus in 1976, numerous previously unknown pathogenic 
viruses have been discovered. Moreover, in recent years, several viruses have widely expanded their 
territory causing the death of an increasing number of people. Since the publication in 1992 of the 
Institute of Medicine (IOM) report, Emerging Infections – Microbial Threats to Health in the 
United States, and its update in 2003, Microbial Threats to Health – Emergence, Detection and 
Response, the concept of new and emerging diseases has captured the general attention.4 Over the 
past decade there has been a renewed public and official concern about infectious diseases as a 
major health threat, and the terms “emerging” and “re-emerging” infectious diseases (EIDs) have 
entered the vocabulary of medical science. Newly emerging infections are those that have not 
previously been recognized in man. Re-emerging infections are those that existed in the past, but 
are now rapidly increasing either in incidence or in geographical / human host range. Infections 
similar to those that we now define as EIDs have for millennia threatened the survival of human 
societies who share ecosystems with rapidly evolving microbial organisms and their non-human 
hosts, vectors, and reservoirs. As far as viral EIDs are concerned, comparison of historical and 
modern emerging diseases suggests that their determinants are largely the same: i) viral (mutation, 
natural selection, virus evolution and adaptation), ii) human and iii) ecological.5 
Several among the emerging infectious diseases are also classified as neglected tropical diseases 
(NTDs) which, according to WHO, are hidden diseases as they affect almost exclusively extremely 
poor populations living in remote areas of Africa, Asia and the Americas, beyond the reach of 
health services. Among the NTDs with the highest-burden there are 13 parasitic (helmintic and 
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protozoal) and bacterial tropical infections, and 20 ectoparasitic, fungal and viral infections. Each 
year NTDs kill approximately 534,000 people worldwide. 
The European Parliament recognized that NTDs have not received the attention they deserve from 
EU actions. Neglected diseases are given low priority because they have low mortality, occur 
almost exclusively in poor developing countries, offer negligible marketable and profitable issues. 
Thus, for the pharmaceutical industry, which carries out the main research and development of new 
drugs, it is too costly and risky to invest in drugs for diseases essentially occurring in low-income 
countries where public spending on drugs is less than 6 USD, compared to ~ 240 USD spent in 
countries belonging to the organization for Economic Cooperation and Development (OECD). It is 
estimated that less than 10% of the world’s biomedical research funds are dedicated to problems 
dealing with 90% of the world’s burden of disease. 
If NTDs are defined as a group of infectious tropical diseases in developing countries that are both 
poverty-promoting and long-lasting in their health impact, then arboviruses (arthropod-borne 
viruses) certainly qualify as NTDs. These viruses belong to taxonomically diverse groups 
representing at least 8 virus Families and 14 Genera. There are currently 534 viruses registered in 
the International Catalogue of Arboviruses, 134 of which are known to cause disease in humans and 
approximately 40 to infect livestock. The most significant arboviruses causing human illness belong 
to the Families Flaviviridae, Bunyaviridae and Togaviridae.6 
Some zoonotic infectious agents have largely been in the hands of scientists and public officials 
associated with animal health and agriculture. These include, for example, agents that cause 
substantial morbidity and mortality in livestock or poultry, especially the agents that cause “foreign 
animal diseases”. Other zoonotic infectious agents have been associated with public health. These 
include, for example: 1) the rabies virus; 2) many arthropod-borne viruses (as well as bacteria and 
protozoa); 3) several rodent-borne viruses (and bacteria); 4) primate-borne agents. Despite all this, 
it seems that the concept of new and emerging zoonotic diseases has not been fully exploited, 
especially given the overriding realization that nearly all of the emergent disease episodes that have 
caught the public attention in the past 15 years have involved zoonotic infectious agents.4 
 
The Flaviviridae family includes single-stranded positive-sense RNA (ssRNA+) viruses, which 
cause significant diseases in humans and animals. They are distributed into three genera: the 
Hepacivirus genus includes, as sole representative, the Hepatitis C virus (HCV) [agents such as GB 
virus-A and GB virus-A-like, GB virus-D and GBV-C or hepatitis G virus, although closely related 
to HCV, represent unassigned members of Flaviviridae]; the Flavivirus genus comprises Yellow 
Fever, West Nile, Dengue Fever, Japanese Encephalitis and Tick-Borne Encephalitis viruses; the 
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Pestivirus genus comprises Bovine Viral Diarrhoea (BVDV), Border Disease and Classical Swine 
Fever viruses. 
 
HCV is a major cause of human hepatitis.7 The WHO estimates that over 170 million people 
worldwide are presently infected by this virus.8,9 Most infections become persistent, and about 60% 
progress towards chronic liver disease. Chronic HCV infection can lead to development of 
cirrhosis, hepatocellular carcinoma and liver failure.10,11 Pegylated interferon, in combination with 
ribavirin, is used in the clinic for HCV infections. Unfortunately, this therapy has limited efficacy 
and is often associated with severe, adverse events.12 
 
Flaviviruses are human pathogens prevalent throughout the world and cause a range of acute febrile 
illness, encephalites and hemorrhagic diseases. Flaviviruses are small, spherical, enveloped viruses 
containing an approximately 11K-nucleotide, positive-sense RNA genome. The viral RNA contains 
a single open reading frame which, when translated, gives rise to a poly-protein that is co- and post-
translationally processed by viral and cellular proteases into three structural proteins (capsid [C], 
pre-membrane [prM], the precursor form of [M], and envelope [E]) and seven non-structural 
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). The non-structural proteins are 
responsible for various enzymatic activities, including RNA-dependent RNA polymerase (NS5) 
(RdRp), helicase (NS3) and protease, and together form the replicase complex (RC) that primarily 
functions to carry out viral genome replication. The structural proteins, along with the host-derived 
lipid bilayer and a single copy of the RNA genome, assemble to form the flavivirus virion. The 
latter is 50 nm in diameter, with a relatively smooth outer surface that is constructed from 180 
copies of both the major E protein and the small M protein.13 
The vectorborne transmission of Yellow Fever Virus (YFV) occurs via the bite of an infected 
mosquito, primarily Aedes or Haemagogus spp. Nonhuman and human primates are the main 
reservoirs of the virus, with anthroponotic (human-to-vector-to-human) transmission occurring. 
There are three transmission cycles for YFV: sylvatic (jungle), intermediate (savannah), and urban. 
The sylvatic (jungle) transmission cycle involves transmission of the virus between nonhuman 
primates and mosquito species found in the forest canopy. The virus is transmitted via mosquitoes 
from monkeys to humans when the humans encroach into the jungle during occupational or 
recreational activities. In Africa, an intermediate (savannah) cycle involves transmission of YFV 
from tree hole-breeding Aedes spp. to humans living or working in jungle border areas. In this 
cycle, the virus may be transmitted from monkeys to humans or from human to human via these 
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mosquitoes. The urban transmission cycle involves transmission of the virus between humans and 
urban mosquitoes, primarily Aedes aegypti. 
Yellow fever occurs in sub-Saharan Africa and tropical South America, where it is endemic and 
intermittently epidemic. Most yellow fever disease in humans is due to sylvatic or intermediate 
transmission cycles. However, urban yellow fever occurs periodically in Africa and sporadically in 
the Americas. In Africa, natural immunity accumulates with age, and thus, infants and children are 
at highest risk for disease. In South America, yellow fever occurs most frequently in unimmunized 
young men who are exposed to mosquito vectors through their work in forested or transitional 
areas. 
Humans infected with YFV experience the highest levels of viremia and can transmit the virus to 
mosquitoes shortly before onset of fever and for the first 3–5 days of illness. Given the high level of 
viremia, bloodborne transmission theoretically can occur via transfusion or needlesticks. 
There is no cure for yellow fever. Treatment is symptomatic, aimed at reducing the symptoms for 
the comfort of the patient. Vaccination, available since the late 1930s, is the most important 
preventive measure against yellow fever. The vaccine is safe, affordable and highly effective, and 
appears to provide protection for 30–35 years or more. The vaccine provides effective immunity 
within one week for 95% of persons vaccinated; nevertheless, its use is not systematic in many 
areas.14 Therefore, YFV continues to be responsible for a significant disease burden. WHO 
estimates that up to 200,000 cases of yellow fever (YF) still occur each year, resulting in 
approximately 30,000 deaths. The vast majority (~ 90%) of cases and deaths takes place in sub-
Saharan Africa, where YF is a major public health problem occurring in epidemic patterns. Africa 
also experiences periodic, yet unpredictable outbreaks of urban YF. Thirty-two African countries 
are now considered at risk, with a total population of 610 million people, among which more than 
219 million live in urban settings. YF is endemic in ten South and Central American countries and 
in several Caribbean islands. Although the disease usually causes only sporadic cases and small 
outbreaks, nearly all major urban centres in the American tropics have been re-infested with Aedes 
aegypti and most urban dwellers are vulnerable because of low immunization coverage. Latin 
America is now at greater risk of urban epidemics than at any time in the past 50 years. Also the 
risk of international spread is greater than before.15-17 
Dengue Virus (DENV) infections may occur asymptomatically, produce a mild self-limiting acute 
febrile illness, dengue fever (DF) (50 to 100 million cases yearly), or a life-threatening illness, 
dengue haemorrhagic fever (DHF) (250,000 to 500,000 yearly, case fatality ratio = 1-5%)15 DENV 
infections are a serious cause of morbidity and mortality in most tropical and sub-tropical countries, 
mainly Southeast and South Asia, Central and South America, and the Caribbean. According to 
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WHO estimates, there are approximately 2.5 billion people at risk of infection.18 DENV infections 
are currently endemic in over 100 tropical and non-tropical countries, and imported cases have been 
reported in several non-endemic countries. The rise in incidence has been marked by an expanding 
geographical distribution of DENV and of its mosquito vector Aedes aegypti, which is found 
worldwide between latitudes 35ºN and 35ºS.19 
West Nile Virus (WNV) is maintained and transmitted through an enzootic cycle involving birds as 
main amplifying hosts, and ornithophilic mosquitoes of the genus Culex as main vectors. Human 
and horses are only incidental hosts in the transmission cycle of WNV. Both are dead-end hosts for 
the virus since the intensity and duration of viraemia are insufficient to allow infection of biting 
mosquitoes.20 Despite that, infections by WNV may have dramatic consequences in both human 
and equine populations, and the recent emergence of WNV in North America has clearly illustrated 
its possible impact for human public health. An estimated 16,000 people in the United States have 
become ill from West Nile virus since 1999, and more than 600 have died. A far greater number of 
people have probably been infected without knowing it because they did not have any symptoms. 
Outside North America, regular outbreaks also occur in Africa, Europe, and Asia. In 1996-97, for 
example, an outbreak near Bucharest, Romania, infected more than 500 people and killed about 50. 
There are no valid statistics on the number of people infected worldwide. What is known is that, 
since its first appearance, WNV caused over 18,000 cases, 800 human deaths, and a large but 
indeterminate number of equine deaths. The huge extension of WNV in the Americas has revealed 
other unexpected modes of transmission of the virus in humans, mainly through blood donation or 
organ transplantation, but also through intra-uterine contamination or sporadic transmission by 
breast-feeding.21 
 
Pestivirus infections of domesticated livestock cause significant economic losses worldwide. 
They cause a range of clinical manifestations, including abortion, teratogenesis, respiratory 
problems, chronic wasting disease, immune system dysfunction and predisposition to secondary 
viral and bacterial infections. BVDV can also establish a persistent infection (PI) in animals, that 
succumb or remain viremic throughout life and serve as continuous virus reservoirs. Furthermore, 
BVDV also shows the ability to cross the placenta of susceptible animals causing a variety of fetal 
infections.22,23 
With the exception of YFV and BVDV, no vaccines exist against Flaviviridae pathogens, as well as 
no selective antiviral drugs are yet available in the clinic to prevent and/or treat their infections. The 
only exceptions are two protease inhibitors, recently approved by FDA for the treatment of HCV 
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infections.24-27 Hence the need to continue studies aimed at identifying new lead compounds 
targeted at virus-specifc steps of the Flaviviridae replication cycle. 
 
Human respiratory syncytial virus (RSV) was first isolated in 1956 from a laboratory 
chimpanzee with upper respiratory tract disease.28 Respiratory syncytial virus (RSV) is a cause of 
acute respiratory tract infections in persons of all ages and is the most common cause of lower 
respiratory tract infection in children aged <1 year. By the age of 2 years, almost all children have 
been infected, and re-infection is a common occurrence. RSV transmission occurs by inoculation of 
nasopharyngeal or ocular mucous membranes after contact with fomites or secretions containing 
RSV.  The most common route of transmission is direct contact, but droplets have also been 
implicated. RSV causes seasonal outbreaks worldwide. Patients at risk for serious RSV infection 
include infants aged <6 months, infants born before 35 weeks of gestation and infants and children 
with underlying lung disease or congenital heart disease.29 
The World Health Organization estimates that RSV causes 64 million infections and 160,000 deaths 
annually.28 
RSV is classified in the genus Pneumovirus of the family Paramyxoviridae.30 Two strains, subtypes 
A and B, have been identified and often circulate concurrently in annual epidemics.31 RSV is an 
enveloped virus with a single-stranded negative-sense RNA genome of 15.2 kb. There are animal 
versions of RSV, including bovine RSV (BRSV) and pneumonia virus of mice (PVM), suggesting 
that species jumping occurred during the evolution of these viruses. However, there is no animal 
reservoir for human RSV. Viral gene expression and RNA replication occur in the cytoplasm, and 
virions acquire a lipid envelope by budding through the plasmid membrane. Virions are 
pleomorphic and include spheres and long, fragile filaments. The negative-sense RNA genome 
contains a short 3’-extragenic leader region, 10 viral genes in a linear array and a 5’-trailer region. 
Each gene is transcribed into a separate, capped, polyadenylated mRNA encoding a single viral 
protein, except in the case of the M2 mRNA, which contains two overlapping open reading frames 
that are expressed by a ribosomal stop-restart mechanism into two distinct proteins, M2-1 and M2-
2. 
Five RSV proteins are involved in nucleocapsid structure and/or RNA synthesis. The nucleocapsid 
N protein tightly encapsidates genomic RNA as well as its positive-sense replicative intermediate, 
called the antigenome. This provides protected, flexible templates and probably reduces detection of 
these viral RNAs by host cell toll-like receptors (TLRs) and intracellular RNA recognition helicases 
that initiate innate immune responses through interferon (IFN) regulatory factors and nuclear factor 
ĸB (NF- ĸB). The large L protein is the major polymerase subunit and contains the catalytic 
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domains. The P phosphoprotein is an essential cofactor in RNA synthesis and also is thought to 
associate with free N and L to maintain them in soluble form for assembly of and interaction with 
nucleocapsids. The M2-1 and M2-2 proteins are factors involved, respectively, in transcription  and 
in modulating the balance between transcription and RNA replication. 
Four other RSV proteins associate with the lipid bilayer to form the viral envelope. The matrix M 
protein lines the inner envelope surface and is important in virion morphogenesis. The heavily 
glycosylated G, fusion F, and small hydrophobic SH proteins are transmembrane surface 
glycoproteins. G and F are the only virus neutralization antigens and are the two major protective 
antigens. 
G protein. The attachment G protein can be divided into an intracellular domain, a transmembrane 
domain, and a large ectodomain. The latter contains a highly conserved central motif between 
aminoacids 164 and 176 that constitutes the putative receptorbinding site. The changes are 
concentrated in two hypervariable regions that flank the highly conserved central region of the G 
protein ectodomain: the first variable region is located in the amino(N)-terminal part of the protein 
preceding the conserved region and the second variable region is located in the carboxy(C)-terminal 
end. The domain located near the C-terminal region has been reported to provide a reliable proxy 
for the entire G gene variability and has subsequently been used in phylogenetic analysis for 
molecular epidemiological studies and to assign isolates to genotypes.32 
 
 
 
Fig. 3.The 298-amino acid attachment glycoprotein of the A2 strain of HRSV is subdivided into the five domains: I, a cytoplasmic 
domain; II, a transmembrane domain; III and V, heavily glycosylated and variable subdomains of the ectodomain; and IV, the 
nonglycosylated central subdomain of the ectodomain (Adapted from Gorman J. J., Jennifer L. Kimm-Breschkin Mc, Norton R. S., 
Barnham K. J.; Antiviral Activity and Structural Characteristics of the Nonglycosylated Central Subdomain of Human Respiratory 
Syncytial Virus Attachment (G) Glycoprotein; 2001).33  
 
F protein. The F protein directs viral penetration by membrane fusion and also mediates fusion of 
infected cells with their neighbors to form syncytia. F is synthesized as a precursor, F0, which is 
activated by cleavage by furin-like intracellular host protease. This cleavage occurs at two sites 
(amino acids 109/110 and 136/137). This yields in amino-to-carboxy-terminal order, F2 (109 amino 
acids), p27    (27 amino acids), and F1 (438 amino acids). F2 and F1 remain linked by a disulfide 
bond and represent the active form. 
 
I II III IV V 
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Fig. 4. RSV F protein structure 
 
During its transport through the secretory pathway, the F protein is glycosylated by several enzyme 
activities in the endoplasmic reticulum (ER) and Golgi complex. Depending on the RSV isolate, the 
F protein amino acid sequence can contain up to 5 potential N-linked glycosylation sites. However, 
experimental evidence suggests that in the mature F protein, the F1 subunit is glycosylated at a 
single site, N500, while the F2 subunit is glycosylated at two different sites, namely N27 and N70. 
Recent reports suggest that N500 plays a role in F protein-mediated fusion possibly by interacting 
with the heptad repeat regions. In contrast, the role played by N27 and N70 in the functionality of 
the F protein remains to be established. 
Evidence that maturation of the N-linked glycans of the respiratory syncytial virus (RSV) 
glycoproteins is required for virus-mediated cell fusion.34 The mature F protein is expressed as a 
homotrimer on the cell surface. The ectodomain of the F1 transmembrane subunit contains two 
heptad repeat regions, HR1 and HR2, and an N-terminal fusion peptide. 
Processing of the F0 precursor has been proposed to generate a “metastable” F1/F2 complex. In one 
proposed model, receptor binding triggers conformational changes in the metastable F protein, 
resulting in insertion of the N-terminal fusion peptide into the target cell membrane. The HR1 and 
HR2 heptad repeat regions then interact to form a six-helix bundle structure. According to this 
model, formation of the six-helix bundle structure facilitates membrane fusion by bringing the viral 
and cellular membranes into close apposition.35 
SH protein. SH is present as an unmodified 7.5 kDa species. Molecular modelling studies also 
favored the pentamer, and suggested SH adopts a circular structure with a central pore. Several 
studies have indicated SH affects membrane permeability.36 The role that the SH protein plays 
during virus infection is unclear. It appears to be dispensable for virus replication in tissue culture, 
and recombinant viruses in which the SH protein was deleted grew better in HEp-2 cells. These 
studies suggested that the SH protein exerted a negative effect on virus induced membrane fusion in 
tissue culture, providing evidence that it may play a regulatory role during membrane fusion. 
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However, the absence of a direct interaction between the SH and F proteins suggests that the SH 
protein is unlikely to assist the F protein in mediating the membrane fusion process (Low K.W. et 
al.; 2008). 
RSV gene expression and RNA replication. The polymerase enters the genome at or near its 3-
end, and the genes are transcribed into individual mRNAs by sequential start-stop-restart synthesis 
that is guided by short transcription signals flanking the genes. RNA replication involves synthesis 
of the full-length positive-sense antigenome that in turn is copied into progeny genomes. 
With RSV, processive transcription depends on the M2-1 protein, which is essential for viral 
viability. In its absence, transcription terminates nonspecifically within several hundred nucleotides 
and results in reduced expression of NS1 and NS2 alone. 
The other product of the M2 gene, the M2-2 protein, is not essential but appears to downregulate 
transcription in favour of RNA replication as infection progresses.37 
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2.0 Challenges for antiviral research vs pathogenic RNA viruses 
Since RNA virus zoonoses cannot be eradicated, countermeasures will always be needed to prevent 
/ treat the related human diseases. Some of them will increase in incidence over coming decades, as 
expanding population, failure of vector control, effects of global warming on vector distribution and 
spread, together with other factors are likely to increase the rate of contact between humans and 
sources of infection. Other diseases will become less prevalent, as changes in human behaviour 
reduce exposure to the etiologic agents and vaccines are introduced or more widely applied. 
Because it is better to prevent a disease than to treat it, vaccines are an essential weapon in the fight 
against highly pathogenic RNA viruses. However, although being the simplest strategy, vaccination 
would require continuous and capillary immunization across the regions where the etiological 
agents persist. But this represents an unlikely prospect. 
Currently, no specific antiviral therapy exist for diseases due to highly pathogenic RNA viruses. 
Compared to HIV/AIDS, HCV and influenza, RNA viral encephalites and hemorrhagic fevers have 
received much less attention: in part because these diseases occur predominantly in underdeveloped 
countries that lack the infrastructures for clinical trials, in part due to the relevant economic 
resources needed to afford expensive medications. 
Only a single licensed drug, Ribavirin, is of clinical use against some of the emerging / neglected 
infections. However, its efficacy against a few types of viral hemorrhagic fever has been reported 
only in observational studies. Ebola and Marburg hemorrhagic fever present the greatest challenge 
to the development of new antiviral therapies for highly pathogenic RNA viral infections. The basic 
problem can be summarized by noting the striking contrast between the high-tech containment labs 
in which these diseases are studied and the impoverished locations in central Africa where they 
occur. 
The effort to develop effective therapies against highly pathogenic emerging and/or neglected RNA 
viral infections is one of the most challenging in public health. Its success requires intensive 
research at multiple levels, from basic studies of the etiologic agents and their replication 
mechanisms, to medicinal chemistry, efficacy testing in animal models, performance in clinical 
trials. 
 
2.1 Nucleos(t)ide analogues and pro-drugs 
Antiviral nucleoside analogues can be divided into two main classes: 
A- Specific inhibitors: target viral enzymes and show high selectivity indices. 
i) Activated by cellular kinases: 
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a. Target RT (HIV and occasionally HBV). Show a narrow spectrum that 
depends on the high affinity of their TP metabolites for target enzymes. 
b. Target RdRp (RNA+ viruses). Show a wide spectrum that depends on the 
high affinity of their TP metabolites for target enzymes. Different target 
viruses share highly conserved sequences in their polymerization site. 
ii) Activated by viral kinases: 
a. Target DdDp (Herpesviruses). Their narrow spectrum depends on the 
high affinity of their TP metabolites for target enzymes following 
activation by kinases. 
B- Non-specific inhibitors: target cellular enzymes and show low selectivity indices and 
broad-spectrum. 
iii) Activated by cellular kinases: 
a. Ribavirin, targets IMP dehydrogenase 
b. 6-aza-UdR, targets OMP decarboxylase 
Generally speaking, the current antiviral drug armamentarium for prevention and treatment of many 
important viral infections comprises more than 40 compounds that have been officially approved 
for clinical use. Generally speaking, the current antiviral drug armamentarium for prevention and 
treatment of many important viral infections comprises more than 40 compounds that have been 
officially approved for clinical use.38 Three decades after the discovery of HIV, 30 antiretroviral 
drugs are currently used in the clinic. 
Polymerase inhibitors are the largest class of approved antiviral drugs, and nucleosides are the 
largest chemical class therein. Many of them proved highly successful for the treatment of HIV 
(zidovudine, zalcitabine, didanosine, stavudine, abacavir, lamivudine, and emtricitabine), HBV 
(lamivudine, telbivudine and entecavir), and Herpes virus infections (acyclovir, valacyclovir, 
penciclovir, famciclovir, idoxuridine, trifluridine, ganciclovir, valganciclovir, cidofovir, 
fomivirsen), but only few [2’-O-methylcytidine, 2’-C-methylcytidine (and its 3’-valine ester, 
valopicitabine), 2’-C-methyladenosine, 2’-C-methylguanosine, 2’-deoxy-2’-fluoro-2’-C-
methylcytidine, 7-deaza-2’-C-methyladenosine, 7-deaza-7-fluoro-2’-C-methyladenosine, 4’-
azidocyitidine] have been proved effective against HCV in vitro,39-41 and none has been successful 
in the clinic, yet. Nucleoside analogues that target viral polymerases share a common mechanism of 
action. They undergo intracellular activation by kinases to triphosphate forms, after which they 
compete with endogenous nucleoside triphosphates (NTPs) for use as substrates by viral 
polymerases and incorporation into nascent nucleic acid chains. Since most of nucleoside analogues 
lack the necessary 3’-OH group for further chain elongation (or, when present, it is unavailable at 
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the right intermolecular distance with the 5’-PO3-- of the incoming nucleotide, because of sugar 
structure distortions), chain termination ensues. 
Although discovered 40 years ago, ribavirin remains the only approved small molecule drug that is 
active against both DNA and RNA viruses.42 Ribavirin itself is a prodrug that is metabolized to the 
active 5’-monophosphate, -diphosphate and triphosphate in vivo. Ribavirin 5′-monophosphate 
(RMP) inhibits cellular inosine monophosphate dehydrogenase (IMPDH), thereby depleting 
intracellular pools of GTP for viral replication. Ribavirin 5′-triphosphate (RTP) is the major 
metabolite accumulated in vivo. It is an effective inhibitor of viral RNA guanylyl transferase and 
(guanine-7N-)-methyl transferase, contributing to the defective 5′-cap structure of viral transcripts 
and insufficient translation. All the 5′-phosphate forms of ribavirin have been implicated as direct 
inhibitors of viral RNA-dependent RNA polymerase (RdRp). Because human cells lack RdRp, the 
latter appear to be one of the most promising targets for antivirals against RNA viruses. Ribavirin is 
a broad-spectrum antiviral agent and has been used clinically to treat respiratory syncytial, hepatitis 
C, Lassa, Hantaan and La Crosse viruses. Ribavirin has inhibitory activity against WNV infection 
in cell culture.43 However, during a WNV outbreak in Israel in 2000, a high mortality rate (41%) 
was observed in a group of 37 patients who received ribavirin.44 5-Aza-7deazaguanosine (ZX-2401) 
is a broad spectrum inhibitor of the RNA viruses that is less toxic and more active than Ribavirin 
and it inhibits YFV, DENV and WNV.45 
 
2.2 Non-nucleoside inhibitors 
Several non-nucleoside inhibitors (NNIs) are known to target reverse transcriptases (RTs), RdRps 
and proteases. The Food and Drug Administration (FDA) has approved 4 non-nucleoside drugs as 
reverse transcriptase inhibitors (NNRTI’s) of HIV-1. 
The NS5B RdRps of HCV and other Flaviviridae are also seen as attractive targets for the 
development of NNIs. Screening of countless compounds has revealed a variety of inhibitors from 
different structural classes, representative of various heterocyclic systems, which bind to distinct 
allosteric sites on the HCV polymerase. Several small molecules have been reported to display 
inhibitory activity against the HCV helicase46 and a class of benzotriazole-benzimidaole-based 
inhibitors have been disclosed by Bristol-Mers Squibb Pharmaceutical as potent inhibitors of RSV 
entry.47 
5'-Amino-2,4'-biimidazoles constitute a scantily studied group of compounds that may afford an 
interesting new scaffold for lead search. They obey well the 2-0 rule of kinase-likeness,48 they can 
be synthesized on-support from adenine and they contain six points of diversification. Structure of 
5'-amino-2,4'-biimidazole is a rigid rod, but rotation around 2,4’-bond connecting the imidazoles is 
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possible, although hindered. Depending on substituents and pH, there is a possibility for 
intramolecular hydrogen bonding between the 5’-amino proton and the pyridine-like nitrogen of the 
second imidazole ring. This hydrogen bond results in formation of a pseudo six-membered ring 
between the imidazoles thus making the ring system planar. Different twisted conformations 
between the imidazole rings can be evoked by the choice of substituents. The multifaceted core 
structure makes it possible to design a spatially diverse set of compounds using a single scaffold. 
For these reasons 5´-amino-2,4´-biimidazoles form a reasonable basis for finding leads to rare RNA 
viruses though the antiviral activity of this kind of compounds has not been so far demonstrated. 
Another class of potential new leads is offered by 7-substituted 3H-imidazo[2,1-i]purines. 
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Recently a number of different aromatic heterocyclic systems have been proposed as anti-RNA 
virus agents, as illustrated in Figure 1. 
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Figure 1: Templates for anti-RNA-virus agents. 
 
Derivatives 1 have been proposed as RNA-dependent RNA helicase inhibitors.49 Derivative 2 has 
been proposed as internal ribosome entry site (IRES) inhibitors.50 Derivative 3 has been proposed as 
fusion inhibitors.51 Derivative 4 have been proposed as RNA-dependent RNA polymerase (RdRp) 
inhibitors.52
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TABLE 1. RNA VIRUSES CAUSING EMERGING (EI) AND/OR NEGLECTED (NTD) INFECTIONS 
Disease Type # cases / deaths (%CFR) per 
year  
Transmission Prevention / Therapy Agent Family / Genus 
 
BSL 
Dengue fever 
(DF); dengue 
hemorrhagic fever 
(DHF) 
EI, 
NTD 
DF: 50-100 million 
DHF: up to 500.000 (CFR 1-
5%) 
2.5 billion people at risk 
Arthropod-borne (mosquitoes) None Dengue virus 
(DENV) 
 
Flaviviridae/ 
Flavivirus 
RNA+ 
3 
Yellow fever  EI, 
NTD 
200.000 / 30.000 
610 million African people at 
risk 
Arthropod-borne (mosquitoes) Vaccine / No therapy Yellow Fever 
virus(YFV) 
Flaviviridae / 
Flavivirus 
RNA+ 
3 
West Nile 
encephalitis 
EI 18.000 / 800 
No valid statistics for # people 
infected worldwide 
Arthropod-borne 
(mosquitoes) 
Supportive treatment 
only 
West Nile  virus 
(WNV) 
Flaviviridae / 
Flavivirus 
RNA+ 
3 
Hantavirus 
hemorrhagic fever 
EI HFRS: 200.000 (CFR 1- 2%) 
HPS: 200 (CFR 40%) 
Contact with infected rodents (or their 
excretions) 
None Hantavirus Bunyaviridae / 
Hantavirus 
RNA- 
3 
Rift Valley 
hemorrhagic fever 
EI 2006-2007 outbreaks: 684/155 
(CFR: 23%) in Kenya 
Older outbreaks usually CFR 
2% 
Arthropod-borne (mosquitoes) Supportive treatment 
only 
Rift Valley 
Fever virus 
(RVFV) 
Bunyaviridae / 
Phlebovirus 
RNA- 
3 
Ebola hemorrhagic 
fever 
EI 1976 – 2008 outbreaks: 2246 / 
1507 (CFR 67%) 
Source unknown. Contact with infected 
biological fluids or organs. 
None / Supportive 
treatment only 
Ebola virus Filoviridae / Ebola-
like 
RNA- 
4 
Hendra 
encephalitis, 
pneumonia 
EI 1994-2009, 9 cases Mode of transmission unknown (respiratory 
route is suspected. Human infection most 
commonly associated with direct contact with 
infected horses. 
None Hendra virus Paramyxoviridae / 
Henipavirus 
RNA- 
4 
Nipah encephalitis EI 1998 - 2008 outbreaks: 477 / 
252 (CFR 52%) 
Mode of transmission unknown, although a 
respiratory route is suspected. Human infection 
most commonly associated with direct contact 
with infected pigs.  
None / Supportive 
treatment only 
Nipah virus Paramyxoviridae / 
Henipavirus 
RNA- 
4 
Lassa hemorrhagic 
fever 
EI 300.000 / 5000 (CFR 15-20%) Contact with infected rodents (or their 
excretions) 
None /  Ribavirin Lassa virus 
(LASV) 
Arenaviridae / Old 
World Arenavirus 
RNAA 
4 
Venezuelan 
hemorrhagic fever 
EI 200 Contact with infected rodents (or their 
excretions) 
None / Supportive 
treatment only 
Guanarito virus 
(GTOV) 
Arenaviridae / New 
World Arenavirus 
RNAA 
4 
Argentine 
hemorrhagic fever 
EI 30.000 cases since 1951  Contact with infected rodents (or their 
excretions) 
None /  Ig only Junin virus 
(JUNV) 
Arenaviridae / New 
World Arenavirus 
RNAA 
4 
Bolivian 
hemorrhagic fever 
EI  Contact with infected rodents (or their 
excretions) 
None / Supportive 
treatment only 
Machupo virus 
(MACV) 
Arenaviridae / New 
World Arenavirus 
RNAA 
4 
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3.0 Materials and Methods 
Test compounds 
Compounds were dissolved in DMSO at 100 mM, and then diluted in culture medium. 
 
Cells and Viruses 
Cell lines were purchased from American Type Culture Collection (ATCC). The absence of 
mycoplasma contamination was checked periodically by the Hoechst staining method. Cell lines 
supporting the multiplication of RNA and DNA viruses were the following: CD4+ human T-cells 
containing an integrated HTLV-1 genome (MT-4); Madin Darby Bovine Kidney (MDBK) [ATCC 
CCL 22 (NBL-1) Bos Taurus]; Baby Hamster Kidney (BHK-21) [ATCC CCL 10 (C-13) 
Mesocricetus auratus] and Monkey kidney (Vero 76) [ATCC CRL 1587 Cercopithecus Aethiops]. 
Viruses were purchased from American Type Culture Collection (ATCC), with the exception of 
Yellow Fever Virus (YFV). Viruses representative of positive-sense, single-stranded RNAs 
(ssRNA+) were: i) Flaviviridae: yellow fever virus (YFV) [strain 17-D vaccine (Stamaril Pasteur 
J07B01)] and bovine viral diarrhoea virus (BVDV) [strain NADL (ATCC VR-534)]; ii) 
Picornaviridae: human enterovirus B [coxsackie type B5 (CVB-5), strain Ohio-1 (ATCC VR-29)], 
and human enterovirus C [poliovirus type-1 (Sb-1), Sabin strain Chat (ATCC VR-1562)]. Viruses 
representative of negative-sense, single-stranded RNAs (ssRNA-) were: iii) Paramyxoviridae: 
human respiratory syncytial virus (RSV) [strain A2 (ATCC VR-1540)]; iv) Rhabdoviridae: 
vesicular stomatitis virus (VSV) [lab strain Indiana (ATCC VR 1540)]. The virus representative of 
double-stranded RNAs (dsRNA) Reoviridae was reovirus type-1 (Reo-1) [simian virus 12, strain 
3651 (ATCC VR-214)]. DNA virus representatives were: v) Poxviridae: vaccinia virus (VV) 
[vaccine strain Elstree-Lister (ATCC VR-1549)]; vi) Herpesviridae: human herpes 1 (HSV-1) 
[strain KOS (ATCC VR-1493)]. 
 
Cytotoxicity Assays 
Cytotoxicity assays were run in parallel with antiviral assays. Exponentially growing MT-4 
cells were seeded at an initial density of 1x105 cells/ml in 96-well plates in RPMI-1640 medium, 
supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin G and 100 µg/mL 
streptomycin. Cell cultures were then incubated at 37 °C in a humidified, 5% CO2 atmosphere, in 
the absence or presence of serial dilutions of test compounds. Cell viability was determined after 96 
hrs at 37°C by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) method. 
MDBK and BHK cells were seeded in 24-well plates at an initial density of 6x105 and 1x106 
cells/mL, respectively, in Minimum Essential Medium with Earle’s salts (MEM-E), L-glutamine, 
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1mM sodium pyruvate and 25mg/L kanamycin, supplemented with 10% horse serum (MDBK) or 
10% foetal bovine serum (FBS) (BHK). Cell cultures were then incubated at 37 °C in a humidified, 
5% CO2 atmosphere in the absence or presence of serial dilutions of test compounds. Cell viability 
was determined after 48-96 hrs at 37°C by the MTT method. Vero-76 cells were seeded in 24-well 
plates at an initial density of 4x105 cells/mL, in Dulbecco’s Modified Eagle Medium (D-MEM) 
with L-glutamine and 25mg/L kanamycin, supplemented with 10% FBS. Cell cultures were then 
incubated at 37 °C in a humidified, 5% CO2 atmosphere in the absence or presence of serial 
dilutions of test compounds. Cell viability was determined after 48-96 hrs at 37 °C by the crystal 
violet staining method.  
 
Antiviral assays 
Compound’s activity against YFV and Reo-1 was based on inhibition of virus-induced 
cytopathogenicity in BHK-21 cells acutely infected with a m.o.i. of 0.01. Compound’s activity 
against BVDV was based on inhibition of virus-induced cytopathogenicity in MDBK cells acutely 
infected with a m.o.i. of 0.01. Briefly, BHK and MDBK cells were seeded in 96-well plates at a 
density of 5x104 and 3x104 cells/well, respectively, and were allowed to form confluent monolayers 
by incubating overnight in growth medium at 37 °C in a humidified CO2 (5%) atmosphere. Cell 
monolayers were then infected with 50 µL of a proper virus dilution in maintenance medium 
[MEM-Earl with L-glutamine, 1mM sodium pyruvate and 0.025g/L kanamycin, supplemented with 
0.5% inactivated FBS] to give an m.o.i of 0.01. After 1 hr, 50 µL of maintenance medium, without 
or with serial dilutions of test compounds, were added. After a 3-/4-day incubation at 37 °C, cell 
viability was determined by the MTT method.  
Compound’s activity against CVB-5, Sb-1, VV, HSV-1 and RSV was determined by plaque 
reduction assays in infected cell monolayers. To this end, Vero 76-cells were seeded in 24-well 
plates at a density of 2x105 cells/well and were allowed to form confluent monolayers by incubating 
overnight in growth medium [Dulbecco's Modified Eagle Medium (D-MEM) with L-glutamine and 
4500 mg/L D-glucose and 0.025g/L kanamycin, supplemented with 10% FBS] at 37 °C in a 
humidified CO2 (5%) atmosphere. Then, monolayers were infected for 2 hrs with 250 µL of proper 
virus dilutions to give 50-100 PFU/well. Following removal of unadsorbed virus, 500 µL of 
maintenance medium [D-MEM with L-glutamine and 4500 mg/L D-glucose, supplemented with 
1% inactivated FBS] containing 0.75% methyl-cellulose, without or with serial dilutions of test 
compounds, were added. Cultures were incubated at 37°C for 2 (Sb-1 and VSV), 3 (CVB-5, VV 
and HSV-1) or 5 days (RSV) and then fixed with PBS containing 50% ethanol and 0.8% crystal 
violet, washed and air-dried. Plaques were then counted. 
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Linear regression analysis 
The extent of cell growth/viability and viral multiplication, at each drug concentration 
tested, were expressed as percentage of untreated controls. Concentrations resulting in 50% 
inhibition (CC50 or EC50) were determined by linear regression analysis.  
 
HCV replicon assays 
A human hepatoma cell line (Huh-7) bearing the HCV genotype 1b replicon (GS4.1 cells), 
kindly provided by C. Seeger (Fox Chase University, Philadelphia, PA, USA) through Idenix 
Pharmaceuticals, was grown in D-MEM supplemented with 10% FBS, 2 mM L-glutamine, 110 
mg/L sodium pyruvate, 0.1 mM non-essential amino acids, 100 U/mL penicillin, 100 µg/mL 
streptomycin and 0.5 mg/mL G418 (Invitrogen). For dose-response testing, GS4.1 cells were seeded 
in 96-well plates at a density of 7.5x103 cells/well in 50 µL medium containing two-fold serial 
dilutions of test compounds (highest concentration, 75 µM). Huh-7 cells lacking the HCV replicon 
served as negative controls. Plates were then incubated for 72 hrs at 37 °C in a humidified, 5% CO2 
incubator. Inhibition of HCV replication was measured by quantification of the viral NS4A protein 
using an enzyme-linked immunosorbent assay (ELISA) as follows: plates were fixed for 1 min with 
1:1 acetone–methanol, washed twice with PBS containing 0.1% Tween 20, left for 1 h at room 
temperature with TNE buffer containing 10% FBS, and then incubated for 2 hrs at 37 °C with the 
anti-NS4A mouse monoclonal antibody A-236 (ViroGen, Watertown, MA, USA) diluted in the 
same buffer. After three washes with PBS containing 0.1% Tween 20, plates were incubated for 1 h 
at 37 °C with anti-mouse immunoglobulin G–peroxidase conjugate in TNE buffer containing 10% 
FBS. After further washing as above, the reaction was developed with o-phenylenediamine (Zymed, 
San Francisco, CA, USA). The reaction was stopped after 30 min with 2N H2SO4 and absorbance 
was determined at 492 nm using a Sunrise Tecan (Durham, NC, USA) spectrophotometer. EC50 
values were determined from % inhibition vs compound concentration data, using a sigmoidal non-
linear regression analysis based on four parameters, with Tecan Magellan software. For cytotoxicity 
evaluation, Huh-7 and GS4.1 cells were treated with compounds as described above, and cellular 
viability was monitored using the Cell Titer 96 Aqueous One Solution cell proliferation assay 
(Promega). CC50 values were determined from the % cytotoxicity vs compound concentration data 
with Tecan Magellan software, as described above.  
Molecular analysis of drug-resistant mutants. Plaque purified virus was subjected to RNA 
extraction, RT-PCR and genome sequencing to identify the mutation patterns responsible for drug 
resistance. Viral RNAs from wt and drg-resistant mutants were obtained using the QIAamp viral 
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RNA minikit (QIAGEN), starting from 140 µL of cell-free viral suspensions, each containing about 
106 PFU/mL, in order to determine the nucleotide sequence of the mutated genes. Reverse 
transcriptions were carried out using the Superscript II enzyme (INVITROGEN) and cDNAs were 
amplified by PCR using Platinum Pfx polymerase (INVITROGEN), following the manufacturer’s 
protocol. 
PCR fragments were purified using the QIAquick PCR Purification kit (QIAGEN) and analyzed 
using the cycle-sequencing method (CIBIACI service, University of Firenze). Both DNA strands 
were sequenced with specific primers. The comparative analysis of the chromatograms allowed us 
to deduce the mutation pattern responsible for drug resistance. 
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4.0 5-Acetyl-2-Arylbenzimidazoles as potent and selective inhibitors 
of BVDV and HCV 
Premises 
Our interest on the chemistry and biological properties of benzimidazoles has led us to 
synthesize numerous derivatives endowed with analgesic-antinflammatory53,54 and choleretic55,56 
activities, as well as with a chloropromazine-like activity in the conditioned avoidance 
response57,58and, more recently, with antiproliferative and antiviral activities.59-62 
In this context, we have described the series of 2-[4-substituted naphtyl]- (1),59 2-[4-
substituted diphenyl]- (2),60 2-[4-substituted styryl]-benzimidazoles (3)61 and 1-substituted-2-
[(benzotriazol-1/2-yl)methyl benzimidazoles (4) and (5),62 endowed with selective activity, at 
micromolar level, against Respiratory Syncytial virus (RSV) and some members of the Flaviviridae 
family (Fig. 1). 
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Fig. 1 
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As part of a pluriennal program in this area,59-62 very recently we described new 2-phenyl-
benzimidazoles [compounds 6 in Fig. 2], which have been evaluated in cell-based assays for 
cytotoxicity and activity against a panel of RNA and DNA viruses.76 Thirty-nine compounds 
exhibited antiviral activity at concentrations comprised between 0.1 and 10 µM, and four of them 
were outstanding for their potency against VV (6a, R=5,6-diCl; R1=4-NO2) or BVDV (6b, R=5-
NO2; R1=H; 4c, R=5-NO2; R1=COCH3; 6d, R=5,6-diCl; R1=COCH3), with EC50 = 0.1, 1.5, 0.8 and 
1.0 µM, respectively. In enzyme assays, 6b and 6d inhibited at low µM concentrations the RNA-
dependent RNA polymerase (RdRp) of BVDV and HCV, respectively. This suggested that 2-
phenylbenzimidazoles could be attractive leads for further development of inhibitors of poxviruses, 
pestiviruses and even HCV. Therefore, we decided to carry on our program to evaluate whether this 
type of compounds, purposely modified, could be improved in both potency and spectrum of 
antiviral activity. 
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Fig. 2 
 
Focusing on the derivatisation of the 5-acetyl group on the benzimidazole, by using typical 
reagents of carbonyl group as hydroxylamine, semicarbazide and thiosemicarbazide, we designed 
and synthesized derivatives 7-31 (Table 1) in order to evaluate the influence of this modification on 
the antiviral activity. 
In support of our hypothesis was the example of the many benzimidazole derivatives 
reported in the literature, where the presence of a carboxylic or tetrazolyl group at position 5 of the 
benzimidazole ring [as in compounds 32-34 (Fig. 3)] allowed inhibition of the HCV RdRp at very 
low IC50 values.77-79 
In our opinion, the presence of an electron withdrawing substituent, such as the acetyl group 
in compounds 7-12 and their derivatives 13-31, could represent a good strategy to improve the 
pharmacophoric properties of this class of compounds. Thus, we decided to proceed in two stages. 
First, we afforded the simple modification of the acetyl group, as in compounds 7-31. Once verified 
that this type of substitution could lead to selective BVDV inhibitors, we prepared benzimidazoles 
35-61 (Table 2) in form of both simple acetyl derivatives and corresponding thiosemicarbazones 
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and semicarbazones, characterized by an increased lipophilicity due to the cyclohexyl substitution 
at position 1, as for the above mentioned compounds 32-34. 
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Fig. 3 
 
In addition, we tested the effect of the isosteric replacement, at position 2, of unsubstituted 
and substituted phenyl rings with different aromatic rings, such as furan and pyridine, which are 
present in the potent HCV RdRp inhibitors 62-63 (Fig. 4) described by other Authors.80,81 
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Fig. 4 
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Biology 
5-acetyl-2-arylbenzimidazole derivatives were tested in cell-based assays for cytotoxicity 
and antiviral activity against representative members of a number of virus families (Tables 1 and 2). 
In addition to the Flaviviridae BVDV and YFV, among ssRNA+ viruses we tested two 
picornaviruses, (human enterovirus B (coxsackie virus type B5, CVB-5,) and human enterovirus C 
(polio virus type-1, Sb-1). Among double-stranded RNA (dsRNA) viruses, we tested reovirus type-
1 (Reo-1). Among ssRNA− viruses we tested a paramyxovirus (human respiratory syncytial virus, 
RSV) and a rhabdovirus (vesicular stomatitis virus, VSV). Two representatives of DNA viruses 
were also included: human herpesvirus 1 (herpes symplex type-1, HSV-1) and vaccinia virus (VV). 
2’-C-methyl-guanosine, 2’-C-methyl-cytidine, 6-aza-uridine, mycophenolic acid and 
acycloguanosine were used as reference inhibitors. Cytotoxicity was evaluated in parallel with the 
antiviral activity. 
As far as the activity against Flaviviridae is concerned, nine compounds (26-28, 30, 31, 53, 
56, 57 and 60) exhibited selective activity against BVDV in the low micromolar range (EC50 = 0.8-
8.0 µM). In particular, derivatives 28 and 31 showed the most potent anti-BVDV activity (EC50 = 
0.83 ± 0.09 and 0.80 ± 0.06 µM, respectively; see dose-response curve in Fig. 5A) and, like 
compounds 26, 57 and 60, were non cytotoxic at concentrations up to 100 µM. 
 
Fig. 5. Dose-response curves of compd 31 from cell-based assays against BVDV (A) and HCV (B).  
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Other compounds (11, 20, 36-38, 42 and 61) exhibited activity against BVDV at higher µM 
concentrations (EC50 = 16-23 µM). Notewhorthy, compound 38 exhibited a selective, although not 
very potent, activity also against YFV (CC50 >100 µM; EC50 = 13.4 ± 1.1 µM), whereas compound 
35 showed activity against YFV (CC50 >100 µM; EC50 = 13.2 ± 1.5 µM), but not against BVDV. 
When tested against representatives of other virus families (Table 1 and 2), 5-acetyl-2-
arylbenzimidazoles resulted mainly inactive. Exceptions were: compound 20 and 35 which, besides 
BVDV, also inhibited CVB-5 (CC50 >100 µM; EC50 = 43 µM) and RSV (CC50 >100 µM; EC50 = 25 
µM), respectively; and compound 43, active only against CVB-5 (CC50 >100 µM; EC50 = 47 µM). 
SAR studies allow to conclude that derivatisation of the 5-acetyl group led to a significant 
improvement in the anti-BVDV activity (compounds 7-11); transformation into ketoximes allowed 
to achieve higher anti-BVDV potency (20); the conversion into semicarbazones also allowed to 
achieve an increase in potency (26); finally, the replacement of a semicarbazide with a 
thiosemicarbazide to obtain the thiosemicarbazones allowed to achieve fairly low EC50 values (28 
and 31). On the contrary, no significant extension of the antiviral spectrum was obtained, the only 
exception being compounds 20, 35 and 37. 
Introduction of a cyclohexyl substituent at position 1 (derivatives 35-61) failed to prove 
useful in improving the anti-BVDV potency. However, compounds 35-38, 42, 48, 53, 57, 59-61 
resulted active against this virus, the most potent being, again, the thiosemicarbazones (53, 57, 60,  
61). Moreover, susbstitution with cyclohexyl (derivatives 35-41) allowed the appearance of 
antiviral activities against different viruses: YFV and RSV, in the case of compounds 35 and 37, 
and YFV in the case of compound 38. 
Structure-activity relationship studies indicate that the acetyl group as such, or its 
corresponding hydroxyethyl derivatives, are unable to promote antiviral activity in the series of N-
1-unsubstituted benzimidazoles. Only when the phenyl bears a 2,4-dimethoxy group at position 2 
(as in the above cited compound 11), the improvement in anti-BVDV activity resulted higher than 
that obtained previously.21 As a cycloexyl substitution at position 1 of the benzimidazole takes 
place, some compounds (35-38, 42, 48, 53, 57, 59-61) exhibit anti-BVDV activity, the most active 
being those bearing the most lipophilic susbstituents in the phenyl ring (2,4-OCH3 = Cl > OCH3). 
Bioisosteric replacement of the phenyl with a furanyl or pyridinyl ring was partially successful in 
the case of 59 (EC50 = 26 µM) and fairly good in the case of compound 60 (EC50 = 8 µM). 
Due to its interesting activity against BVDV, compound 31 was also tested against HCV in 
a subgenomic replication assay that allows viral replication in a human hepatoma cell line (GS4.1). 
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In this assay, 31 selectively inhibits the HCV replication with an EC50 of 1.11 ± 0.15 µM (Table 3 
and dose-response curve in Fig. 5B). 
 
Table 3. Comparative activity of compd 31 against BVDV and HCV in cell-based assays. 
 
 
aCell-based 
Compd BVDV HCV-1b 
 
bCC50 cEC50 dCC50 eEC50 
31 >100 0.80 ± 0.06 11.3 ± 1.5 1.11 ± 0.15 
 
    
aData represent mean values for three independent determinations. 
bCompound concentration (µM) required to reduce the viability of mock-infected MDBK cells by 50%, as determined by the MTT method. 
cCompound concentration (µM) required to achieve 50% protection of MDBK cells from BVDV-induced cytopathogenicity, as determined by the 
MTT method. 
dCompound concentration (µM) required to reduce the viability of GS4.1 cells by 50%, as described in the Experimental section. 
eCompound concentration (µM) required to achieve 50% protection of GS4.1 cells from cytopathogenicity, as described in the Experimental section. 
 
 
Chemistry 
The preparation of compounds 7-31 and 35-61 was achieved according to the sequence of 
reactions of Scheme 1. From the commercially available bromoacetofenone (a) (Jansen), we 
prepared the necessary intermediates (b,c) following a known procedure for (b)58, whereas (c) was 
obtained for the first time in DMSO at 70°C for 3h. The diamine (d) was previously described by 
W. Borsche and J. Barthenheier,82 while (e) is a new compound. Ring closure to benzimidazoles 
was accomplished in two different ways. As the N-unsubstitued diamine (d) was used, condensation 
with the bisulfite salts of the aldheydes f-m yielded the desired compounds 7-12, 42, 43. In the case 
of the N-cyclohexyl substituted diamine (e), we had to carry on the reactions with the aldehydes f-n 
in DMF/water (30:1), at room temperature for 1h, in the presence of oxone to obtain compounds 35-
41. In both cases yields were very satisfactory (ranging from 58-98%). The intermediates 7, 8, 10-
12, have been described previously by some of us (G.P., M.L), while compounds 9, 42, 43 are 
described here for the first time. Compounds 13-15 were obtained on reduction by means of NaBH4 
in aqueous ethanol of the parent 10-12. The ketoximes 16-21 were obtained from the ketones 7-12 
by reaction with hydroxylamine. The acetylderivatives 7-12 and 35-43 were alternatively converted 
into the corresponding semicarbazones 22-26 and 44-52, respectively, and thiosemicarbazones 27-
31 and 53-61, respectively, using in turn semicarbazide hydrochloride and thiosemicarbazide in 
refluxing ethanol and in the presence of sodium acetate or glacial acetic acid, respectively. 
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The elucidation of all novel compounds was supported by elemental analyses and 1H-NMR 
spectra, that are fully consistent with the described structures. In addition, for certain compounds 
(14, 17, 22, 24, 25, 29, 39, 48, 50, 53, 55, 61) 13C-NMR spectra were recorded to further ascertain 
the localisation of the carbon atoms external to the hetero-rings. Examination of these 13C-NMR 
spectra (vide infra) allowed us to confirm that a few variations are concerned with the presence of 
substituents in the phenyl moiety at position 2 of the benzimidazole ring, whereas the chemical 
shifts of C-8, C-9, and of C=S and C=O in side chains, were almost coincident. 
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l=cycloexyl
m= 3'-furyl
n=2'-pyridinyl
iii
v
vi
Scheme1- i, in ethanol in sealed tube at 100°C; ii, in DMSO at 70°C for 3 h; iii, in refluxing ethanol for 4-5h; iv, in DMF at r.t for 
1h in the presence of oxone; v, NaBH4 in ethanol/water; vi, NH2OH  in ethanol   ; vii, semicarbazidehydrochloride  
in ethanol and in the presence of  sodium acetate; viii, thiosemicarbazide in ethanol , water and acetic acid.
vii
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Table 1. Cytotoxicity and antiviral activity of 2-phenylbenzimidazoles, and reference compds, against representatives of ssRNA+ (BVDV, YFV, CBV-5, Sb-1), ssRNA- (RSV, VSV), dsRNA (Reo-1) and dsDNA (VV, HSV-1) viruses°. 
MDBK BVDV BHK YFV Reo-1 Vero-76 CVB-2 Sb-1 RSV VSV VV HSV-1 Compd X R R’ CC50a EC50b CC50c EC50d EC50e CC50f EC50g EC50h EC50i EC50j EC50k EC50l 
7 C=O H Ph >100 100 ND ND ND ND ND ND ND ND ND ND 
8 C=O H Ph(4’-Cl) ND ND ND ND ND ND ND ND ND ND ND ND 
9 C=O H Ph(4’- CF3) >100 15 ND ND ND ND ND ND ND ND ND ND 
10 C=O H Ph(4’-OCH3) 58 >58 40 >40 ND >100 >100 >100 ND ND >100 ND 
11 C=O H Ph(2’,4’-OCH3) 73 21 (3) 50 >50 ND >100 >100 >100 ND ND >100 ND 
12 C=O H Ph(2’,3’,4’-OCH3) >100 >100 ND ND ND ND ND ND ND ND ND ND 
13 CH-OH H Ph(4’-OCH3) >100 >100 >100 >100 ND >100 >100 >100 ND ND >100 ND 
14 CH-OH H Ph(2’,4’-OCH3) >100 >100 >100 >100 ND >100 >100 >100 ND ND >100 ND 
15 CH-OH H Ph(2’,3’,4’-OCH3) 60 >60 
 
60 >60 ND 
 
>100 >100 >100 ND ND >100 ND 
 
16 CN-OH H Ph >100 >100 ND ND ND ND ND ND ND ND ND ND 
17 CN-OH H Ph(4’-Cl) 37 18 33 >33 ND ND ND ND ND ND ND ND 
18 CN-OH H Ph(4’- CF3) 55 >55 ND ND ND ND ND ND ND ND ND ND 
19 CN-OH H Ph(4’-OCH3) 44 >44 44 >44 ND >100 >100 >100 ND ND >100 ND 
20 CN-OH H Ph(2’,4’-OCH3) >100 17 (5) >100 >100 >100 >100 43 (2) >100 >100 >100 >100 >100 
21 CN-OH H Ph(2’,3’,4’-OCH3) >100 >100 
 
>100 >100 ND 
 
>100 >100 >100 ND ND >100 ND 
 
22 C=N-NH-CO-NH2 H Ph >100 50 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
23 C=N-NH-CO-NH2 H Ph(4’-Cl) >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
24 C=N-NH-CO-NH2 H Ph(4’- CF3) >100 45 ND ND ND ND ND ND ND ND ND ND 
25 C=N-NH-CO-NH2 H Ph(4’-OCH3) 25 11 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
26 C=N-NH-CO-NH2 H Ph(2’,4’-OCH3) >100 2.5 (40) 
 
>100 >100 >100 
 
80 >80 >80 ND >80 80 ND 
 
27 C=N-NH-CS-NH2 H Ph 32 3.8 (8) 32 >32 ND >100 >100 >100 ND >100 >100 ND 
28 C=N-NH-CS-NH2 H Ph(4’-Cl) >100 0.8 (125) >100 >100 ND >100 >100 >100 ND >100 >100 ND 
29 C=N-NH-CS-NH2 H Ph(4’- CF3) 5 >5 5 >5 ND 22 >22 >22 ND ND ND ND 
30 C=N-NH-CS-NH2 H Ph(4’-OCH3) 13 1.8 (7) 13 >13 >13 >100 >100 >100 ND >100 >100 ND 
31 C=N-NH-CS-NH2 H Ph(2’,4’-OCH3) >100 0.8 (125) 
 
28 >28 >28 
 
>100 >100 >100 >100 >100 ND >100 
 
*Reference Compds               
2’-C-methyl-guanosine >100 2.0±0.1 (>50) >100 
1.8±0.1 
(>56) 
0.7±0.2 
(143) >100 55±2 50±0.5 >100 >100 >100 >100 
2'-C-methyl-cytidine >100 3.2±1.0 (>31) >100 >100 
17±1.0 
(>6) >100 
18±1.5 
(>6) 
8.7±1.4 
(>11)  >100 >100 >100 >100 
6-Aza-uridine >100 >100 >100 >100 >100 12.5 >12.5 >12.5 1.4±0.2 (9) >12.5 >12.5 >12.5 
Mycophenolic acid 2.8 >2.8 >100 >100 20 13 >13 >13 >13 >13 1.7±0.1 (8) >13 
Acycloguanosine >100 >100 
 
>100 >100 >100 
 
>100 >100 >100 >100 >100 >100 3.0±0.1 (>33) 
 
° Data represent mean values + SD for three independent determinations. For values where SD is not shown, variation among duplicate samples was less than 15%. 
a Compound concentration (µM) required to reduce the viability of mock-infected MDBK cells by 50%, as determined by the MTT method. 
b Compound concentration (µM) required to achieve 50% protection of MDBK cells from BVDV-induced cytopathogenicity, as determined by the MTT method. 
c Compound concentration (µM) required to reduce the viability of mock-infected BHK cells by 50%, as determined by the MTT method. 
d Compound concentration (µM) required to achieve 50% protection of BHK cells from YFV-induced cytopathogenicity, as determined by the MTT method. 
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e Compound concentration (µM) required to achieve 50% protection of BHK cells from Reo-1-induced cytopathogenicity, as determined by the MTT method. 
f Compound concentration (µM) required to reduce the viability of mock-infected Vero-76 cells by 50%. as determined by the MTT method. 
g Compound concentration (µM) required to reduce the plaque number of CVB-2 by 50% in Vero-76 monolayers. 
h Compound concentration (µM) required to reduce the plaque number of Sb-1 by 50% in Vero-76 monolayers. 
i Compound concentration (µM) required to reduce the plaque number of RSV by 50% in Vero-76 monolayers. 
j Compound concentration (µM) required to reduce the plaque number of VSV by 50% in Vero-76 monolayers. 
k Compound concentration (µM) required to reduce the plaque number of VV by 50% in Vero-76 monolayers. 
l Compound concentration (µM) required to reduce the plaque number of HSV-1 by 50% in Vero-76 monolayers. 
( ) Selectivity Index: CC50/EC50 
ND= not determined 
Table 2. Cytotoxicity and antiviral activity of 2-phenylbenzimidazoles, and reference compds, against representatives of ssRNA+ (BVDV, YFV, CBV-5, Sb-1), ssRNA- (RSV, VSV), dsRNA (Reo-1) and dsDNA (VV, HSV-1) viruses°. 
MDBK BVDV BHK YFV Reo-1 Vero-76 CVB-2 Sb-1 RSV VSV VV HSV-1 Compd X R R’ CC50a EC50b CC50c EC50d EC50e CC50f EC50g EC50h EC50i EC50j EC50k EC50l 
35 C=O c-hexyl Ph >100 60 >100 13 >100 80 >80 >80 25 ND >80 >80 
36 C=O c-hexyl Ph(4’-Cl) >100 23 >100 >100 >100 >100 >100 >100 >100 ND >100 >100 
37 C=O c-hexyl Ph(4’-CF3) 52 23 33 >33 >33 35 >35 >35 20 ND >35 >35 
38 C=O c-hexyl Ph(4’-OCH3) >100 21 >100 13 >100 30 >30 >30 >30 >30 >30 >30 
39 C=O c-hexyl Ph(2’,4’-OCH3) 21 >21 8.5 >8.5 >8.5 70 >70 >70 >70 >70 >70 >70 
40 C=O c-hexyl 3’-Furyl >100 >100 77 >77 ND 80 >80 ND ND ND >80 >80 
41 C=O c-hexyl 2’-Pyridinyl >100 >100 >100 >100 ND 90 >90 ND >90 ND >90 >90 
42 C=O H 3’-Furyl >100 22 98 >98 ND >100 >100 ND >100 ND >100 >100 
43 C=O H c-hexyl >100 >100 
 
>100 >100 >100 
 
>100 47 >100 >100 ND >100 >100 
 
44 C=N-NH-CO-NH2 c-hexyl Ph >100 >100 >100 >100 >100 ND ND ND ND ND ND ND 
45 C=N-NH-CO-NH2 c-hexyl Ph(4’-Cl) >100 >100 >100 >100 >100 ND ND ND ND ND ND ND 
46 C=N-NH-CO-NH2 c-hexyl Ph(4’-CF3) >100 >100 >100 >100 >100 ND ND ND ND ND ND ND 
47 C=N-NH-CO-NH2 c-hexyl Ph(4’-OCH3) 54 >54 ND ND ND ND ND ND ND ND ND ND 
48 C=N-NH-CO-NH2 c-hexyl Ph(2’,4’-OCH3) 36 22 19 >19 ND 20 >20 >20 ND ND >20 >20 
49 C=N-NH-CO-NH2 c-hexyl 3’-Furyl >100 100 ND ND ND ND ND ND ND ND ND ND 
50 C=N-NH-CO-NH2 c-hexyl 2’-Pyridinyl >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
51 C=N-NH-CO-NH2 H 3’-Furyl >100 60 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
52 C=N-NH-CO-NH2 H c-hexyl >100 44 
 
>100 >100 >100 
 
>100 >100 >100 >100 >100 >100 >100 
 
53 C=N-NH-CS-NH2 c-hexyl Ph 24 4.5 38 9 >38 20 >20 >20 >20 >20 >20 >20 
54 C=N-NH-CS-NH2 c-hexyl Ph(4’-Cl) >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
55 C=N-NH-CS-NH2 c-hexyl Ph(4’-CF3) >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
56 C=N-NH-CS-NH2 c-hexyl Ph(4’-OCH3) 32 7 ND ND ND 40 >40 >40 >40 ND >40 >40 
57 C=N-NH-CS-NH2 c-hexyl Ph(2’,4’-OCH3) >100 4 (24) 17 >17 >17 20 >20 >20 >20 >20 >20 >20 
58 C=N-NH-CS-NH2 c-hexyl 3’-Furyl >100 >100 >100 >100 ND 25 >25 >25 ND >25 >25 >25 
59 C=N-NH-CS-NH2 c-hexyl 2’-Pyridinyl 41 26 24 >24 ND 20 >20 >20 ND >20 >20 >20 
60 C=N-NH-CS-NH2 H 3’-Furyl >100 8 (12) >100 >100 >100 100 >100 100 >100 >100 >100 >100 
61 C=N-NH-CS-NH2 H c-hexyl >100 16 
 
24 >24 ND 
 
>100 >100 >100 >100 >100 >100 >100 
 
Reference Compds             
2’-C-methyl-guanosine >100 2.0±0.1 (>50) 
 
>100 1.8±0.1 (>56) 
0.7±0.2 
(143) 
 
>100 55±2 50±0.5 >100 >100 >100 >100 
2'-C-methyl-cytidine >100 3.2±1.0 (>31) >100 >100 
17±1.0 
(>6) >100 
18±1.5 
(>6) 
8.7±1.4 
(>11)  >100 >100 >100 >100 
6-Aza-uridine >100 >100 >100 >100 >100 12.5 >12.5 >12.5 1.4±0.2 (9) >12.5 >12.5 >12.5 
Mycophenolic acid 2.8 >2.8 >100 >100 20 13 >13 >13 >13 >13 1.7±0.1 (8) >13 
Acycloguanosine >100 >100 
 
>100 >100 >100 
 
>100 >100 >100 >100 >100 >100 3.0±0.1 (>33) 
Legend as in Table 1 
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5.0 1-substituted 2-[(benzotriazol-1/2 yl)methyl]benzimidazoles as 
potent and selective inhibitors of RSV 
Premises 
Recently, Yu et al. reported that 1-[(dialkylamino)alkyl]-2-[(benzotriazol-1/2-yl)methyl] benzimi-
dazoles are endowed with potent anti-RSV activity.83,84 Interestingly, replacement of the 
benzotriazole element with a benzimidazol-2-one or a 6/7-azabenzimidazol-2-one, and the 
introduction of substituents on both the benzimidazole and benzimidazolone N-atoms, led to even 
more potent anti-RSV agents.85,86  (Fig. 1). 
 
 
 
Fig. 1. Known benzimidazole derivatives with anti-RSV activity. 
 
 
Indeed, the (dimethylamino)ethyl chain, which characterized first-generation compounds, conferred 
excellent antiviral properties; however, it was also associated with metabolic lability.87 The 
introduction on said N-atoms of 4-hydroxybutyl and cyclopropyl substituents, respectively, 
produced a compound (BMS-433771) endowed with anti-RSV activity in animals following oral 
administration. 
The 1-[(dialkylamino)alkyl]-2-[(benzotriazol-1/2-yl)methyl]benzimidazoles, evaluated for antiviral 
activity by Yu et al., had been prepared by Prof. Boido and his group as analgesics, as well as for 
other pharmacological purposes.88,89 Therefore, following the report from Bristol researchers, the 
antiviral activity of related 1-substituted 2-[(benzotriazol-1/2-yl)methyl]benzimidazoles, prepared in 
the past but not examined by Yu et al., has been evaluated in our lab. In particular, some 5-
substituted derivatives, as well as compounds bearing at position 1 the peculiar and cumbersome 
(quinolizidinyl)alkyl residues, have been the object of our previous study. 
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The 1-substituents consisted of either simple (dialkylamino)alkyl chains or, as was the case for 18 
derivatives, lupinyl, epilupinyl, and homolupinyl residues characterized by the presence of the 
bulky, strongly basic and lipophilic quinolizidine (octahydro-2H-quinolizine) nucleus (Fig. 2). 
 
 
 
Fig. 2. 1-substituted 2-[(benzotriazol-1/2 yl)methyl]benzimidazoles.90 
 
 
A total of fortythree 1-substituted 2-[(benzotriazol-1/2-yl)methyl]benzimidazoles have been tested 
for cytotoxicity and antiviral activity against a panel of RNA and DNA viruses and, among them, 
thirtynine compounds exhibited potent activity against RSV, in many cases with EC50 values below 
50 nm.90 Briefly, SAR studies suggested that: 
• the presence of substituents at position 5 of the benzimidazole ring leads to an increase in 
cytotoxicity; 
• the most potent antiviral activity correlates with Cl in R and either EtNMe2 or PrNMe2 in 
R’; 
• replacement of Cl in R with H, NO2, CF3 or COCH3 leads to lower potency; 
• replacement in R’ of EtNMe2 with EtNEt2 or lupinyl leads to a progressive increase of 
potency; 
• homolupinyl derivates are the most potent, regardless of whether R is H or Cl. 
 
Biology 
Due to the fact that the presence of substituents at position 5 of the benzimidazole ring led to an 
increase in cytotoxicity, especially in (quinolizidinyl)alkyl derivatives, two new analogues (ASCC 
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459 and ASCC 460) bearing a methyl group at this position (R’) were synthesized and evaluated in 
cell-based assays for cytotoxicity and anti-RSV activity (Table 1). Like their counterparts (P-149-1  
and FP-FS-8) carrying a Cl at the R’ position, ASCC 459 and ASCC 460 resulted potent RSV 
inhibitors (EC50 = 0.030 µM). Noteworthy, the presence of a methyl group at position 5 of the 
benzimidazole ring led to a two-fold decrease of the cytotoxicity for MT-4 cells of the 
(quinolizidinyl)alkyl derivative (compare ASCC 460 with FP-FS-8). 
N
N
C
H2
N
N N
R
R'
 
 
 
 
In order to define the spectrum of the their antiviral activity, ASCC 459 and ASCC 460 were tested 
against representatives of ssRNA+ (BVDV, YFV, CBV-5, Polio-1), ssRNA- (VSV), dsRNA (Reo-1) 
and dsDNA (VV, HSV-1) viruses. 
As shown in Table 2, ASCC 459 and ASCC 460 did not exhibit cytotoxicity for the other cell lines 
tested, nor activity against viruses different from RSV. As previously reported,90 FP-FS-8 exhibited 
a moderate anti-BVDV and -CVB2 activity, whereas ASCC 460 failed to inhibit the latter two 
viruses. 
 
Mode of action studies 
To get more insights into the step of the RSV replication cycle inhibited by ASCC 459, a time-
dependent drug addition assay was performed. In this kind of experiment, the contemporary 
infection of all cultured cells, so as to avoid repeated infection cycles, is fundamental. Thus, Vero 
cells were infected for 1 h at 20° C with RSV, using a multiplicity of infection (m.o.i.) of 5 PFU/cell. 
The unadsorbed virus was removed by extensive washing and ASCC 459 (50 µM), Dextran Sulfate 
 
Table 1. Cytotoxicity for MT-4 and Vero-76 cell lines and anti-RSV activity of new benzimidazole derivatives. 
 
Compd achronim R R’ MT-4 aCC50 
Vero76 
bCC50 
 
 
RSV 
 cEC50 
ASCC 459 CH3 CH2CH2N(CH3)2 >100 >100 0.030 + 0.002 
ASCC 460 CH3 CH2CH2-Lupinyl 41 >100 0.030 + 0.003 
P-149-1 Cl CH2CH2N(CH3)2 ≥100 >100 0.030 + 0.001 
FP-FS-8 Cl CH2CH2-Lupinyl 16 45 0.020 + 0.003 
 
Reference compd    
6-aza-uridine 0.3 ≥12.5 1.4 + 0.2 
a) Compound concentration [µM] required to reduce the viability of MT-4 cells by 50%, as determined by the MTT method. 
b) Compound concentration [µM] required to reduce the viability of Vero-76 cells by 50%, as determined by the MTT method. 
c) Compound concentration + SD [µM] required to reduce the plaque number of RSV by 50% in Vero-76 monolayers.  
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(40 µg/mL), and Ribavirin (80 µM) were added to duplicate cultures at different times after the end 
of infection, i.e. (immediately, or 2, 4, 6, 8, 10, 12, 14, 16 hrs thereafter). Virus titres (PFU/mL) were 
determined at the end of a 3 day incubation at 37°C. As reference inhibitors we used Ribavirin, 
which blocks the viral RNA synthesis, and Dextran Sulphate (DS), which is an inhibitor of RSV 
adsorption, as well as of the subsequent fusion of the viral envelope with the cell membrane.91 
N
N
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As shown in Fig. 3, ASCC 459 behaved like Dextran Sulphate, giving rise to a significant inhibition 
of the virus titre only if added within two hrs after the end of infection. Viceversa, consistently with 
previous reports.92 Ribavirin completely inhibited the production of RSV infectious progeny even if 
added as late as 10 hours after the end of infection. 
 
 
 
 
Table 2. Cytotoxicity and antiviral activity of 1-substituted 2-[(benzotriazol-1/2 yl) methyl] benzimidazoles derivatives against representatives of ssRNA+ (BVDV, YFV, 
CBV-5, Sb-1), ssRNA- (VSV), dsRNA (Reo-1) and dsDNA (VV, HSV-1) viruses°. 
MDBK BVDV BHK YFV Reo-1 Vero-76 CVB2 Sb-1 VSV VV HSV-1 Compd 
achronim R R’ CC50a EC50b CC50c EC50d EC50e CC50f EC50g EC50h EC50i EC50j EC50k 
ASCC 459 CH3 
CH2CH2N(CH3)
2 
>100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
ASCC 460 CH3 
CH2CH2-
Lupinyl >100 >100 55 >55 >55 >100 >100 >100 >100 >100 >100 
P-149-1 Cl CH2CH2N(CH3)
2 
ND ND ND ND ND >100 ND ND ND ND ND 
FP-FS-8 Cl CH2CH2-Lupinyl 55 14 
 
20 >20 ND 
 
45 26 ND ND ND ND 
 
Reference 
Compds 
  
  
 
   
 
      
2’-C-methyl-
guanosine 
  
>100 2.0±0.1 (>50) >100 
1.8±0.1 
(>56) 
0.7±0.2 
(143) >100 55±2 50±0.5 >100 >100 >100 
2'-C-methyl-
cytidine 
  
>100 3.2±1.0 (>31) >100 >100 
17±1.0 
(>6) >100 
18±1.5 
(>6) 
8.7±1.4 
(>11)  >100 >100 >100 
6-Aza-uridine   >100 >100 >100 >100 >100 12.5 >12.5 >12.5 >12.5 >12.5 >12.5 
Mycophenolic 
acid 
  2.8 >2.8 >100 >100 20 13 >13 >13 >13 1.7±0
.1 (8) >13 
Acycloguanosin
e 
  
>100 >100 
 
>100 >100 >100 
 
>100 >100 >100 >100 >100 3.0±0.1 (>33) 
 
° Data represent mean values + SD for three independent determinations. For values where SD is not shown, variation among duplicate samples was less than 15%. 
a Compound concentration (µM) required to reduce the viability of mock-infected MDBK cells by 50%, as determined by the MTT method. 
b Compound concentration (µM) required to achieve 50% protection of MDBK cells from BVDV-induced cytopathogenicity, as determined by the MTT method. 
c Compound concentration (µM) required to reduce the viability of mock-infected BHK cells by 50%, as determined by the MTT method. 
d Compound concentration (µM) required to achieve 50% protection of BHK cells from YFV-induced cytopathogenicity, as determined by the MTT method. 
e Compound concentration (µM) required to achieve 50% protection of BHK cells from Reo-1-induced cytopathogenicity, as determined by the MTT method. 
f Compound concentration (µM) required to reduce the viability of mock-infected Vero-76 cells by 50%. as determined by the MTT method. 
g Compound concentration (µM) required to reduce the plaque number of CVB-2 by 50% in Vero-76 monolayers. 
h Compound concentration (µM) required to reduce the plaque number of Sb-1 by 50% in Vero-76 monolayers. 
i Compound concentration (µM) required to reduce the plaque number of VSV by 50% in Vero-76 monolayers. 
j Compound concentration (µM) required to reduce the plaque number of VV by 50% in Vero-76 monolayers. 
k Compound concentration (µM) required to reduce the plaque number of HSV-1 by 50% in Vero-76 monolayers. 
( ) Selectivity Index: CC50/EC50 
ND = not determined 
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Fig. 3. Time-dependent drug addition assay. See text for details. 
 
To assess whether ASCC 459 is targeted at virus entry (a two-step process consisting of adsorption 
of virus to cell receptors, followed by fusion of its envelope with the cell membrane), an experiment 
was performed (Table 3) by infecting Vero monolayers with RSV (m.o.i. > 5 PFU/cell) for 2 hrs at 
37°C, in the absence or presence of ASCC 459. At the end of infection, cell monolayers were 
washed three times with cold D-MEM to remove both the unadsorbed virus and the drug, and were 
incubated for additional 96 hrs either in the absence or in the presence of the same ASCC 459 
concentrations used in the 2 hr infection period. It is worth noting that length and temperature of 
this particular infection procedure allows both adsorption of the virus to cell receptors and 
subsequent fusion of its envelope with the cell membrane. Therefore, unlike what happened in the 
experiment shown in Fig. 3, the addition of ASCC 459 at the end of infection did not impair the 
final virus yield, compared to untreated controls. 
 
 
Table 3. Different ASCC 459 treatment modes in an RSV acute infection assay at high m.o.i. 
Virus Titre (PFU/mL) 
ASCC 459 [µM] 
Drug present only by the 
end of the 2 hr infection 
period 
Drug present only during the 
2 hr infection period 
Drug present during and after 
the 2 hr infection period 
10 3.6 x 105 5.3 x 105 2.9 x 104 
1 5.1 x 105 3.4 x 105 2.0 x 104 
0.1 3.8 x 105 2.6 x 105 6.7 x 104 
0.01 4.6 x 105 6.7 x 105 3.0 x 105 
No drug 3.9 x 105 
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As also shown in Table 3, when ASCC 459 was removed after the 2 hr infection period, full RSV 
multiplication took place, no matter how high was the drug concentration used during the infection 
period. Viceversa, when the treatment was prolonged after the infection period, ASCC 459 was able 
to reduce significantly the virus titre even in the presence of drug concentrations as low as 0.1 µM. 
On the one hand, these results suggest that ASCC 459 does not inhibit the virus adsorption step; in 
fact, if it had, RSV would have been removed during washing of the inoculum, thus preventing 
infection of the monolayer. On the other hand, a fusion inhibitor would permit virus adsorption, 
thereby allowing the infection to proceed upon removal of the drug. 
A characteristic of the RSV infection in vitro is that infected cells can fuse with adjacent uninfected 
cells to form giant syncytia. Also this process is mediated by the envelope F protein that mediates 
entry of the virus into the cell by fusion of the viral envelope with the cell membrane. Therefore, if 
ASCC 459 were a fusion inhibitor, it could also be expected to prevent syncytia formation in a co-
culture consisting of a mix of RSV-infected and uninfected cells. Therefore, 1 x 104 Vero cells 
infected with RSV (at a m.o.i. = 0.1 PFU/cell) were cocultured with 1x 105 uninfected Vero cells in 
the absence or in the presence of various concentrations of ASCC 459 or Dextran Sulfate. The 
number of syncytia was determined with a light microscope when the untreated control co-cultures 
showed 90% CPE (day 3). 
As shown in Fig. 4, ASCC 459 inhibited syncytia formation whit an EC50 of 0.03 µM. Dextran 
Sulphate, which was used as reference compound, showed an EC50 of 3.7 µg/mL. This result further 
confirms that ASCC 459 is a fusion inhibitor. 
 
  
Fig. 4. Cocultures of RSV-infected and uninfected Vero cells. See text for details. 
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In vitro selection and genotype mapping of P-149-1 and ASCC 459-resistant 
viruses 
Selective inhibitors of the virus multiplication targeted at specific virus-coded proteins usually 
allow the in vitro selection of resistant variants carrying, in the genes coding for the targeted 
proteins, mutations allowing elusion of inhibition. 
RSV codes for three envelope proteins [G (attachment), F (fusion), and SH (membrane 
permeability)] that are involved in virus entry. In order to get more insights into the mode of action 
of ASCC 459 (and the structurally related P-149-1 congener) and, possibly, to identify their target 
protein(s), resistant variants were selected in vitro by passaging RSV in Vero cells in the presence 
of increasing concentrations of ASCC 459 (or P-149-1). The starting drug concentrations were 0.03 
µM. After 7 passages, mutants resistant to drug concentrations of 3.84 µM (128 fold the EC50) were 
obtained. The control RSV wt was grown in parallel in the absence of drugs and the susceptibility 
of the resistant strain to compound was determined by titration in the presence or in absence of the 
inhibitor. Resistant viruses grown in the absence or presence of the selecting drugs showed similar 
titres, which were also in the same magnitude order of that of the RSV wt. Interestingly, the ASCC 
459- and the P-149-1-resistant mutants showed cross-resistance to P-149-1 and ASCC459, 
respectively. For this reason, it was decided to give priority to the sequencing of the P-149-1 
resistant mutant. 
An aliquot of the latter mutant was subjected to RNA extraction, RT-PCR and genome sequencing 
in order to identify the mutation pattern responsible for drug resistance. 
Purified fragments were added to different specific primers, in order to sequence both strands. 
Analysis of the received chromatograms (with Chromas software, www.technelysium.com.au), 
regarding the RSV wild-type strain, allowed us to obtained the entire nucleotide sequence of G, F 
and SH genes. 
 
G, F and SH nucleotide sequences of the RSV wt 
G gene [894nt] 
ATGTCCAAAAACAAGGACCAACGCACCGCTAAGACATTAGAAAGGACCTGGGACACT
CTCAATCATTTATTATTCATATCATCGTGCTTATATAAGTTAAATCTTAAATCTGTAGCA
CAAATCACATTATCCATTCTGGCAATGATAATCTCAACTTCACTTATAATTGCAGCCAT
CATATTCATAGCCTCGGCAAACCACAAAGTCACACCAACAACTGCAATCATACAAGAT
GCAACAAGCCAGATCAAGAACACAACCCCAACATACCTCACCCAGAATCCTCAGCTTG
GAATCAGTCCCTCTAATCCGTCTGAAATTACATCACAAATCACCACCATACTAGCTTCA
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ACAACACCAGGAGTCAAGTCAACCCTGCAATCCACAACAGTCAAGACCAAAAACACA
ACAACAACTCAAACACAACCCAGCAAGCCCACCACAAAACAACGCCAAAACAAACCA
CCAAGCAAACCCAATAATGATTTTCACTTTGAAGTGTTCAACTTTGTACCCTGCAGCAT
ATGCAGCAACAATCCAACCTGCTGGGCTATCTGCAAAAGAATACCAAACAAAAAACCA
GGAAAGAAAACCACTACCAAGCCCACAAAAAAACCAACCCTCAAGACAACCAAAAAA
GATCCCAAACCTCAAACCACTAAATCAAAGGAAGTACCCACCACCAAGCCCACAGAA
GAGCCAACCATCAACACCACCAAAACAAACATCATAACTACACTACTCACCTCCAACA
CCACAGGAAATCCAGAACTCACAAGTCAAATGGAAACCTTCCACTCAACTTCCTCCGA
AGGCAATCCAAGCCCTTCTCAAGTCTCTACAACATCCGAGTACCCATCACAACCTTCAT
CTCCACCCAACACACCACGCCAG 
F gene [1722nt] 
ATGGAGTTGCTAATCCTCAAAGCAAATGCAATTACCACAATCCTCACTGCAGTCACATT
TTGTTTTGCTTCTGGTCAAAACATCACTGAAGAATTTTATCAATCAACATGCAGTGCAG
TTAGCAAAGGCTATCTTAGTGCTCTGAGAACTGGTTGGTATACCAGTGTTATAACTATA
GAACTAAGTAATATCAAGAAAAATAAGTGTAATGGAACAGATGCCAAGGCAAAATTG
ATAAAACAAGAATTAGATAAATATAAAAATGCTGTAACAGAATTGCAGTTGCTCATGC
AAAGCACACAAGCAACAAACAATCGAGCCAGAAGAGAACTACCAAGGTTTATGAATT
ATACACTCAACAATGCCAAAAAAACCAATGTAACATTAAGCAAGAAAAGGAAAAGAA
GATTTCTTGGTTTTTTGTTAGGTGTTGGATCTGCAATCGCCAGTGGCGTTGCTGTATCTA
AGGTCCTGCACCTAGAAGGGGAAGTGAACAAGATCAAAAGTGCTCTACTATCCACAAA
CAAGGCTGTAGTCAGCTTATCAAATGGAGTTAGTGTCTTAACCAGCAAAGTGTTAGAC
CTCAAAAACTATATAGATAAACAATTGTTACCTATTGTGAACAAGCAAAGCTGCAGCA
TATCAAATATAGAAACTGTGATAGAGTTCCAACAAAAGAACAACAGACTACTAGAGAT
TACCAGGGAATTTAGTGTTAATGCAGGTGTAACTACACCTGTAAGCACTTACATGTTAA
CTAATAGTGAATTATTGTCATTAATCAATGATATGCCTATAACAAATGATCAGAAAAA
GTTAATGTCCAACAATGTTCAAATAGTTAGACAGCAAAGTTACTCTATCATGTCCATAA
TAAAAGAGGAAGTCTTAGCATATGTAGTACAATTACCACTATATGGTGTTATAGATAC
ACCCTGTTGGAAACTACACACATCCCCTCTATGTACAACCAACACAAAAGAAGGGTCC
AACATCTGTTTAACAAGAACTGACAGAGGATGGTACTGTGACAATGCAGGATCAGTAT
CTTTCTTCCCACAAGCTGAAACATGTAAAGTTCAATCAAATCGAGTATTTTGTGACACA
ATGAACAGTTTAACATTACCAAGTGAAGTAAATCTCTGCAATGTTGACATATTCAACCC
CAAATATGATTGTAAAATTATGACTTCAAAAACAGATGTAAGCAGCTCCGTTATCACA
TCTCTAGGAGCCATTGTGTCATGCTATGGCAAAACTAAATGTACAGCATCCAATAAAA
ATCGTGGAATCATAAAGACATTTTCTAACGGGTGCGATTATGTATCAAATAAAGGGGT
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GGACACTGTGTCTGTAGGTAACACATTATATTATGTAAATAAGCAAGAAGGTAAAAGT
CTCTATGTAAAAGGTGAACCAATAATAAATTTCTATGACCCATTAGTATTCCCCTCTGA
TGAATTTGATGCATCAATATCTCAAGTCAACGAGAAGATTAACCAGAGCCTAGCATTT
ATTCGTAAATCCGATGAATTATTACATAATGTAAATGCTGGTAAATCCACCACAAATAT
CATGATAACTACTATAATTATAGTGATTATAGTAATATTGTTATCATTAATTGCTGTTG
GACTGCTCTTATACTGTAAGGCCAGAAGCACACCAGTCACACTAAGCAAAGATCAACT
GAGTGGTATAAATAATATTGCATTTAGTAAC 
SH gene [192nt] 
ATGGAAAATACATCCATAACAATAGAATTCTCAAGCAAATTCTGGCCTTACTTTCACTA
ATACACATGATCACAACAATAATCTCTTTGCTAATCATAATCTCCATCATGATTGCAAT
ACTAAACAAACTTTGTGAATATAACGTATTCCATAACAAAACCTTTGAGTTACCAAGA
GCTCGAGTCAACACA 
 
When compared to the above wt counterparts, the analysis of the G nucleotide sequence of the P-
149-1-resistant variants showed the substitution of adenine (AAA-codon) with guanine (GAA-
codon) in the first nucleotide of the triplet coding for lysine in wt (and glutamic acid in the resistant 
mutant) at position 212. 
An identical mutation was found in the triplet coding for the aa at position 315 of the F protein. 
The SH nucleotide sequence of the resistant virus revealed no mutations whith respect to wt virus. 
The results are summarized in Tab. 5 and Figs. 5 and 6. 
 
Table 4. Mutations in the P-149-1-resistant RSV. 
 
Resistant mutant Protein / aminoacid position Triplet            aminoacid 
G 212 AAAGAA   LysGlu RSVP-149-1 
F 315 AAAGAA   LysGlu 
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RSVwt: lys (AAA) RSVP-149-1: glu (GAA) 
                 
 
 
 
 
 
 
Fig. 5. Chromatograms of G protein in RSVwt and RSVP-149-1 showing the mutated triplet at position 212 
 
RSVwt: lys (AAA)        RSVP-149-1: glu (GAA) 
 
 
 
 
 
  
 
 
 
Fig. 6. Chromatograms of F protein in RSVwt and RSVP-149-1 showing the mutated triplet at position 315. In 
this case, the reverse DNA strands are shown. 
 
In conclusion, the sequence analysis of RSVP-149-1-resistant mutant showed no mutations in the SH 
gene, but one mutation each in the G and F genes at positions 212 and 315, respectively. 
These results suggest that mutations K212E for the G protein and K315E for the F protein correlate 
with the emergence of mutants resistant to P-149-1. Identical results were obtained with ASCC 459. 
A G  A C A A  C  C  A  A  A  A  A  A  G  A  T  C  C  C  A     A G  A  C  A  A  C  C  G  G  A  A  A  A  G  A  T  C  C  C  A   
T  G  T  G  T  G   T  A  G  T  T  T  C  C  A  A  C  A  G  G   G           T  G  T  G  T  G   T  A  G  T  T  C  C C A  A  C  A  G  G   G          
 41 
6.0 References 
1. WHO. The world health report 2007 – a safer future: global public health in the 21st century. 
Geneva: World Health Organization, 2007. 
2. Guerrant, R.L.; Lima, A.A.M.; Davidson, F. Micronutrients and Infection: Interactions and 
Implications with Enteric and Other Infections and Future Priorities. Clin. Infect. Dis. 1999, 
28, 966-86. 
3. Butler, J.C.; Crengle, S.; Cheek, J.E.; Leak A.J.; Lennon, D.; O'Brien, K.L.; Santoshamet, 
M. Emerging infectious diseases among indigenous peoples. Emerg. Infect. Dis. 2001, 7, 
554-5. 
4. Murphy, F.A.; Emerging zoonoses: the challenge for public health and biodefense. Prev. 
Vet. Med. 2008, 86, 216-23. 
5. Morens, M.D.; Folkers, G.B.; Fauci A.S. Emerging infections: a perpetual challenge. 
Lancet. Infect. Dis. 2008, 8, 710-9. 
6. Nalca, A.;  Fellows, P.F.; Whitehouse, C.A. Vaccines and animal models for arboviral 
encephalitides. Antiviral. Res. 60, 153-74. 
7. Hayashi, P.H.; Di Bisceglie, A.M. The progression of hepatitis B- and C-infections to 
chronic liver disease and hepatocellular carcinoma: epidemiology and pathogenesis. Med. 
Clin. North Am. 2005, 89, 371-389. 
8. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in 
collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral Hepat. 
1999, 6, 35-47.  
9. Memon, M.I.; Memon, M.A. Hepatitis C: an epidemiological review. J. Viral Hepat. 2002, 
9, 84-100. 
10. Echevarria-Mayo, J.M. Etiology and pathogenesis of viral hepatitis. Enferm. Infect. 
Microbiol. Clin. 2006, 24, 4-56. 
11. Bosch, F.X.; Ribes , J.; Cleries, R.; Diaz, M. Epidemiology of hepatocellular carcinoma. 
Clin. Liver Dis. 2005, 9, 191-211. 
12. Fried, M.W.; Shiffman, M.L.; Reddy, K.R.; Smith, C.; Marinos, G.; Gonçales, F.L. Jr.; 
Häussinger, D.; Diago, M.; Carosi, G.; Dhumeax, D.; Craxi, A.; Lin, A.; Hoffman, J.; Yu, J. 
Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 
2002, 347, 975-982. 
 42 
13. Patkar, C.G.; Kuhn, R.J. Yellow Fever Virus NS3 Plays an Essential Role in Virus 
Assembly Independent of Its Known Enzymatic Functions. 2008,  J. of Virology, 82, 3342-
52 
14. Monath, T.P. Yellow fever as an endemic/epidemic disease and priorities for vaccination. 
Bull. Soc. Pathol. Exot. 2006, 99, 341-347. 
15. Tolle, M.A. Mosquito-borne diseases. Curr Probl Pediatr Adolesc Helath Care, 2009, 39, 
97-140. 
16. Bray, M. Highly pathogenic RNA viral infections: challenges for antiviral research. 
Antiviral Res. 2008, 78, 1-8. 
17. Gould, A.E.; Solomon T.  Pathogenic flaviviruses. Lancet, 2008, 371, 500-9. 
18. Kurane, I. Dengue hemorrhagic fever with special emphasis on immunopathogenesis. Comp. 
Immunol. Microbiol. Infect. Dis. 2007, 30, 329-40. 
19. Wilder-Smith, A.; Schwartz, E. Dengue in travelers. N. Eng.l J. Med. 2005, 353, 924-32. 
20. Hayes, B.A.; Komar, N.; Nasci, RS.; Montgomery, SP; O'Leary, D.R.; Campbell, G.L. 
Emerg. Inf. Dis. 2005, 11, 1167-73. 
21. Granwehr, B.P.; Lillibridge, K.M., Higgs S., Mason, P.W., Aronson, J.F., Campbell, G.A., 
Barrett, A.D. West Nile virus: where are we now? Lancet. Infect. Dis. 2004, 4, 547-56. 
22. O’Connor, A.M.; Sorden, S.D.; Apley, M.D. Association between the existence of calves 
persistently infected with bovine viral diarrhoea virus and commingling on pen morbidity in 
feedlot cattle. Am. J. Vet. Res. 2005, 66, 2130-2134. 
23. Chase, C.C.; Elmowalid, G.; Yousif, A.A. The immune response to bovine viral diarrhoea 
virus: a constantly changing picture. Vet. Clin. North Am. Food Anim. Pract. 2004, 20, 95-
114. 
24. Bacon, B.R.; Gordon, S.C.; Lawitz, E.; Marcellin, P.; Vierling, J.M.; Zeuzem, S. Boceprevir 
for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011, 364, 1207-
1217. 
25. Jacobson, I.M.; McHutchison, J.G.; Dusheiko, G.; Di Bisceglie, A.M.; Reddy, K.R.; 
Bzowej, N.H. Telaprevir for previously untreated chronic hepatitis C virus infection. N. 
Engl. J. Med. 2011, 364, 2405–2416. 
26. Poordad, F.; McCone, J.; Bacon, B.R.; Bruno, S.; Manns, M.P.; Sulkowski, M.S. Boceprevir 
for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011 364, 1195–1206. 
27. Zeuzem, S.; Andreone, P.; Pol, S.; Lawitz, E.; Diago, M.; Roberts, S. Telaprevir for 
retreatment of HCV infection. N. Engl. J. Med. 2011, 364, 2417–2428. 
28. Collins, P.L. and Graham, B.S. Viral and Host Factors in Human Respiratory Syncytial 
 43 
Virus Pathogenesis. J. Virol. 2008,  82, 2040-55.  
29. O’Connell, K. Use of palivizumab and infection control measures to control an outbreak of 
respiratory syncytial virus in a neonatal intensive care unit confirmed by real-time 
polymerase chain reaction; Journal of Hospital Infection,  2011, 77, 338-342. 
30. Hacking, D.; Hull, J. Respiratory Syncytial Virus Viral Biology and the Host Response; 
Journal of infection; 2002, 45, 18-24;  
31. Morris, S.K.; Dzolganovski, B.; Beyene J.; Sung L.; A meta-analysis of the effect of 
antibody therapy for the prevention of severe respiratory syncytial virus infection; Infectious 
Diseases, 2009. 
32. Fodha, I.; Vabret, A.; Bouslama, L.; Leroux, M.; Legrand, L.; Dina, J.; Gouarin, S.; 
Petitjean, J.; Dewar, J.; Trabelsi, A.; Boujaafar, N.; Freymuth, F.; Molecular diversity of the 
aminoterminal region of the G protein gene of human respiratory syncytial virus subgroup 
B. Pathologie Biologie,  2008, 56, 50–57. 
33. Gorman, J. J.; Jennifer, L.; Kimm-Breschkin, Mc; Norton, R.S., Barnham, K.J. Antiviral 
Activity and Structural Characteristics of the Nonglycosylated Central Subdomain of 
Human Respiratory Syncytial Virus Attachment (G) Glycoprotein. 2001. 
34. Mc Donald, T.P.; Jeffree, C.E.; Li, P.; Rixon, H.W.; Brown, G.; Aitken, J.D.; MacLellan, 
K.; Sugrue, R.J.; Evidence that maturation of the N-linked glycans of the respiratory 
syncytial virus (RSV) glycoproteins is required for virus-mediated cell fusion: The effect of 
alpha-mannosidase inhibitors on RSV infectivity. Virology, 2006, 350,  289-301. 
35. Yunus, A.S.; Jackson, T.P.; Crisafi, K.; Burimski, I.; Kilgore, N.R.; Zoumplis, D.; Allaway, 
G.P.; Wild, C.T.; Salzwedel, K. Elevated temperature triggers human respiratory syncytial 
virus F protein six-helix bundle formation; Virology, 2010, 396, 226–237. 
36. Carter, S.D.; Dent, K.C.; Atkins, E.; Foster, T.L.; Verow, M.; Gorny, P.; Harris, M.; Hiscox, 
J.A.; Ranson, N.A.; Griffin, S.; Barr, J.N. Direct visualization of the small hydrophobic 
protein of human respiratory syncytial virus reveals the structural basis for membrane 
permeability; FEBS Letters, 2010, 584, 2786–2790.  
37. Low K.W. , Tan T., Ng K., Tan B.H., Sugrue R.; The RSV F and G glycoproteins interact to 
form a complex on the surface of infected cells. Biochemical and biophysical research 
communications; 2008, 366, 308-313;  
38. De Clercq, E.; Campo, H.J.; Antiviral prodrugs – development of prodrug success strategies 
for antiviral chemotherapy. Br. J. Pharmacol. 2006,147,1-11. 
39. Carroll, S.S.; Tomassini, J.E.; Bosserman, M.; Getty, K.; Stahlhut, M.W.; Eldrup, A.B.; 
Bhat, B.; Padiglione, D.; Simcoe, A.L.; La Femina, R.; Rutkowski, C.A.; Wolanski, B.; 
 44 
Yang, Z.; Migliaccio, G.; De Francesco, R.; Kuo, L.C.; Mac Coss, M.; Olsen, D.B. 
Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs. J. Biol. 
Chem. 2003, 278, 11979-84. 
40. Klumpp, K.; Lévêque, V.;Le Pogam, S.; Ma, H.; Jiang, W.R.; Kang, H.; Granycome, C.; 
Singer, M.; Laxton, C.; Hang, J.Q.; Sarma, K.; Smith, D.B.; Heindl, D.; Hobbs, C.J.; 
Merrett, J.H.; Symons, J.; Cammack, N.; Martin, J.A.; Devos, R.; Nájera, I. The novel 
nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA 
synthesis and hepatitis C virus replication in cell culture. J. Biol. Chem. 2006, 281, 3793-9. 
41. Benzaria, S.; Bardiot, D.; Bouisset, T.; Counor, C.; Rabeson, C.; Pierra, C.; Storer, R.; Loi, 
A.G.; Cadeddu, A.; Mura, M.; Musiu, C.; Liuzzi, M.; Loddo, R.; Bergelson, S.; Bichko, V.; 
Bridges, E.; E-Scott, C.; Mao, J.; Sommadossi, J.P.; Seifer, M.; Standring, D.; Tausek, M.;  
Gosselin, G.; La Colla, P. 2’-C-Methyl Branched Pyrimidine Ribonucleoside Analogues: 
Potent Inhibitors of RNA Virus Replication. Antivir. Chem. Chemother. 2007, 18, 225-42. 
42. Wu, J.Z.; Lin, C.C.; Hong, Z. Ribavirin, viramidine and adenosine-deaminase-catalysed 
drug activation: implication for nucleoside prodrug design. J. Antimicrob. Chemother. 2003, 
52, 543-6.  
43. Anderson, J.F.; Rahal, J.J. Efficacy of interferon alpha-2b and ribavirin against West Nile 
virus in vitro. Emerg. Infect. Dis. 2002, 8, 107-8. 
44. Chowers, M.Y.; Lang, R.; Nassar, F.; Ben-David, D.; Giladi, M.; Rubinshtein, E.; Itzhaki, 
A.; Mishal, J.; Siegman-Igra, Y.; Kitzes, R.; Pick, N.; Landau, Z.; Wolf, D.; Bin, H.; 
Mendelson, E.; Pitlik, S.D.; Weinberger, M. Clinical characteristics of the West Nile fever 
outbreak, Israel, 2000. Emerg Infect Dis. 2001, 7, 675-8. 
45. Ojwang, J.O.; Ali, S.; Smee, D.F.; Morrey, J.D.; Shimasaki, C.D.; Sidwell, R.W. Broad-
spectrum inhibitor of viruses in the Flaviviridae family. Antiviral. Res. 2005, 68, 49-55. 
46. Diana GD et al. 1997 U.S. patent 5,633,3888. 
47. Yu, K.L.; Zhang, Y.; Civiello, R.L.; Kadow, K.F.; Cianci, C.; Krystal, M.; Meanwell, N.A. 
Fundamental structure-activity relationships associated with a new structural class of 
respiratory syncytial virus inhibitor. Bioorg Med Chem Lett. 2003, 13, 2141-4. 
48. Aronov, A.M.; McClain, B.; Moody, C.S.; Murcko, M.A. Kinase-likeness and kinase-
privileged fragments: toward virtual polypharmacology J. Med. Chem. 2008, 13; 51, 1214-
22. 
49. Wang, Q.M. Drug of the future 2000, 25:933-944. 
 45 
50. Wang, W.; Préville, P.; Morin, N. ; Mounir, S.; Cai, W.; Siddiqui, M.A. Epatite C inibizione 
virale IRES da fenazina e fenazina molecole simili. Bioorg. Med. Chem. Lett. 2000, 10, 
1151-4. 
51. Yu, K.L.; Zhang, Y.; Civiello, R.L.; Kadow, K.F.; Cianci, C.; Krystal, M.; Meanwell, N.A. 
Fundamental structure-activity relationships associated with a new structural class of 
respiratory syncytial virus inhibitor. Bioorg. Med. Chem. Lett. 2003, 13, 2141-4. 
52. Tabarrini, O.; Manfroni, G.; Fravolini, A.; Cecchetti, V.; Sabatini, S.; De Clercq, E.; 
Rozenski, J.; Canard, B.; Dutartre, H.; Paeshuyse, J.; Neyts, J. Synthesis and anti-BVDV 
activity of acridones as new potential antiviral agents. J. Med. Chem. 2006,  49, 2621-7. 
53. Paglietti, G.; Sparatore, F. Dialchilaminoalchilbenzimidazoli d’interesse farmacologico. 
Nota III. Il Farmaco, Ed.Sci., 1972, 27, 335-342. 
54. Paglietti, G.; Boido, V.; Sparatore, F. Dialchilaminoalchilbenzimidazoli di interesse 
farmacologico. Nota IV. Il Farmaco, Ed.Sci., 1974, 30, 505-511. 
55. Paglietti, G.; Sparatore, F. Preparazione di acidi β-benzimidazolil- e indazolil-butirrici quali 
potenziali coleretici. Il Farmaco, Ed. Sci. 1972, 27, 471-479. 
56. Grella, G.; Paglietti, G.; Sparatore, F.; Manca, P.; Satta, M. Sintesi ed attività coleretica di 
acidi 3-(2-aril-5R-benzimidazol-l-il)butanoici. Il Farmaco, Ed. Sci. 1987, 42, 475-490. 
57. Paglietti, G.; Pirisi, M.A.; Loriga, M.; Grella, G.; Sparatore, F.; Satta, M.; Manca, P.; Peana, 
A. Preparazione ed attività farmacologica di 2-(4’R’)benzil-5R-benzimidazoli. Attività 
analgesica e sull’acquisizione di una risposta condizionata di avoidance. Il Farmaco, 
Ed.Sci., 1988, 43, 203-214. 
58. Paglietti, G.; Pirisi, M.A.; Loriga, M.; Grella, G.; Sparatore, F.; Satta, M.; Manca, P. 
Preparazione ed attività farmacologica di 2-(4’R’)fenil-5R-benzimidazoli e 2-(4’piridinil)-
5R-benzimidazoli. Attività analgesica e sull’acquisizione di una risposta condizionata di 
avoidance. Il Farmaco, Ed. Sci., 1988, 43, 215-226. 
59. Vitale, G.; Carta, A.; Loriga, M.; Paglietti, G.; Loddo, R.; Busonera, B.; Collu, D.; La Colla, 
P. 2-Arylbenzimidazoles as antiviral and antiproliferative agents - Part 1. Med. Chem. 2008, 
4, 605-615. 
60. Vitale, G.; Corona P.; Loriga, M.; Carta, A.; Paglietti, G.; La Colla, P.; Busonera, B.; 
Marongiu, E.; Collu, D.; Loddo, R.; 2-Arylbenzimidazoles as antiviral and antiproliferative 
agents - Part 2. Med. Chem. 2009, 5, 507-516. 
61. Vitale, G.; Corona P.; Loriga, M.; Carta, A.; Paglietti, G.; Ibba, C.; Giliberti, G.; Loddo, R.; 
La Colla P.; Marongiu, E. Styrylbenzimidazoles. Synthesis and biological activity - Part 3. 
Med. Chem. 2010, 6, 70-78. 
 46 
62. Tonelli, M.; Paglietti, G.; Boido, V.; Sparatore, F.; Marongiu, F.; Marongiu, E.; La Colla, 
P.; Loddo, R. Antiviral activity of benzimidazole derivatives. I. Antiviral activity of 1-
substituted-2-[(benzotriazol-1/2-yl)methyl]benzimidazoles. Chem. Biodivers. 2008, 5, 2386-
2401. 
63. Hayashi, P.H.; Di Bisceglie, A.M. The progression of hepatitis B- and C-infections to 
chronic liver disease and hepatocellular carcinoma: epidemiology and pathogenesis. Med. 
Clin. North Am. 2005, 89, 371-389. 
64. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in 
collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral Hepat. 
1999, 6, 35-47.  
65. Memon, M.I.; Memon, M.A. Hepatitis C: an epidemiological review. J. Viral Hepat. 2002, 
9, 84-100. 
66. Echevarria-Mayo, J.M. Etiology and pathogenesis of viral hepatitis. Enferm. Infect. 
Microbiol. Clin. 2006, 24, 4-56. 
67. Bosch, F.X.; Ribes , J.; Cleries, R.; Diaz, M. Epidemiology of hepatocellular carcinoma. 
Clin. Liver Dis. 2005, 9, 191-211. 
68. Fried, M.W.; Shiffman, M.L.; Reddy, K.R.; Smith, C.; Marinos, G.; Gonçales, F.L. Jr.; 
Häussinger, D.; Diago, M.; Carosi, G.; Dhumeax, D.; Craxi, A.; Lin, A.; Hoffman, J.; Yu, J. 
Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 
2002, 347, 975-982. 
69. Monath, T.P. Yellow fever as an endemic/epidemic disease and priorities for vaccination. 
Bull. Soc. Pathol. Exot. 2006, 99, 341-347. 
70. O’Connor, A.M.; Sorden, S.D.; Apley, M.D. Association between the existence of calves 
persistently infected with bovine viral diarrhoea virus and commingling on pen morbidity in 
feedlot cattle. Am. J. Vet. Res. 2005, 66, 2130-2134. 
71. Chase, C.C.; Elmowalid, G.; Yousif, A.A. The immune response to bovine viral diarrhoea 
virus: a constantly changing picture. Vet. Clin. North Am. Food Anim. Pract. 2004, 20, 95-
114. 
72. Bacon, B.R.; Gordon, S.C.; Lawitz, E.; Marcellin, P.; Vierling, J.M.; Zeuzem, S.. 
Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011, 
364, 1207-1217. 
73. Jacobson, I.M.; McHutchison, J.G.; Dusheiko, G.; Di Bisceglie, A.M.; Reddy, K.R.; 
Bzowej, N.H. Telaprevir for previously untreated chronic hepatitis C virus infection. N. 
Engl. J. Med. 2011, 364, 2405–2416. 
 47 
74. Poordad, F.; McCone, J.; Bacon, B.R.; Bruno, S.; Manns, M.P.; Sulkowski, M.S. Boceprevir 
for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011 364, 1195–1206. 
75. Zeuzem, S.; Andreone, P.; Pol, S.; Lawitz, E.; Diago, M.; Roberts, S. Telaprevir for 
retreatment of HCV infection. N. Engl. J. Med. 2011, 364, 2417–2428. 
76. Tonelli, M.; Simone, M.; Tasso, B.; Novelli, F.; Boido, V.; Sparatore, F.; Paglietti, G.; Pricl, 
S.; La Colla, P.; Giliberti, G.; Blois, S.; Ibba, C.; Sanna, G.; Loddo, R. Antiviral activity of 
Benzimidazole Derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives, 
Bioorg. Med. Chem. 2010, 18, 2937-2953. 
77. Hashimoto, H.; Mizutani, K.; Yoshida, A.; Japan Tobacco Inc. Japan, U.S. Patent Appl. 
Publ.  US 2003 50, 320; Chem. Abstr., 2003, 138, 238181c. 
78. Priestley, E.S.; Decicco, C.P.; Hudyma, T.W.; Zheng, X. (Bristol- Meyers-Squibb 
Company, USA) PCT Int. Appl. WO 03 26, 587, 3 Apr 2003, C.A, 2003, 138, 287673y, 
896. 
79. Hirashima, S.; Suzuki, T.; Ispida, T.; Noji, S.; Yata, S.; Ando, I.; Komatsu, M.; Ikeda, S.; 
Hashimoto, H. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus 
NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies 
and identification of a potent and highly selective inhibitor JTK-109. J. Med. Chem, 2006, 
49, 4721-4736. 
80. Beaulieu, P.L.; Bös, M.; Bousquet, Y.; Fazal, G.; Gauthier, J.; Gillard, J.; Goulet, S.; La 
Plante, S.; Poupart, M.A.; Lefebvre, S.; Mc Kercher, G.; Pellerin, C.; Austel, V.; Kukolj, G. 
Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and 
preliminary SAR of benzimidazole derivatives. Bioorg. Med. Chem. Lett. 2004, 14, 119-
124. 
81. Beaulieu, P.L.; Bös, M.; Bousquet, Y.; De Roy, P.; Fazal, G.; Gauthier, J.; Gillard, J.; 
Goulet, S.; Mc Kercher, G.; Poupart, M.A.; Valois, S.;  Kukolj, G. Non-nucleoside 
inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-
carboxylic amide derivatives with low-nanomolar potency. Bioorg. Med. Chem. Lett. 2004, 
14, 967-971. 
82. Borsche, W.; Barthenheier, J.; Uber Kern-acylierung nach Friedel-Crafts. II, Liebig’s 
Annalen der Chemie, 1942, 553, 250-259.   
83. Yu, K.L.; Zhang, Y.; Civiello, R. L.; Kadow, K. F.; Cianci, C.; Krystal, M.; Meanwell, N. 
A. Fundamental structure-activity relationship associated with a new structural class of 
respiratory syncytial virus inhibitor. Bioorg. Med. Chem. Lett. 2003, 13, 2141-4.  
 48 
84. K.-L. Yu, R. L. Civiello, M. Krystal, K. F. Kadow, N. A. Meanwell, Patent WO 00/04900, 
2000; Chem. Abstr. 2000, 132, 122625. 
85. Cianci, C  C.; Genovesi, E.V.; Lamb, L.;Medina, I.; Yang, Z.; Zadjura, L.; Yang, H.; 
D'Arienzo, C.; Sin, N.; Yu, K.L.; Combrink, K.; Li, Z.; Colonno, R.; Meanwell N.; Clark, J.; 
Krystal, M.; Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of 
infection. Antimicrob. Agents Chemother. 2004, 48, 2448-54. 
86. Cianci, C.; Yu, K.L.; Combrink, K.; Sin, N.; Pearce, B.; Wang, A.; Civiello R.; Voss, S.; 
Luo G.; Kadow, K.; Genovesi, E. V.; Venables, B.; Gulgeze, H.; Trehan, A.; James, J.; 
Lamb, L.; Medina, J.; Roach, J.; Yang, Z.; Zadjura, L.; Colonno, R.; Clarke, J.; Meanwell, 
N.; Krystal, M. Antimicrob. Agents Chemother. 2004, 48, 413. 
87. Yu, K.L.; Wang, X.A.; Civiello, R.L.; Trehan, A.K.; Pearce, B.C.; Yin, Z., Combrink, K.D.; 
Gulgeze, H.B.; Zhang, Y.; Kadow, K.F.; Cianci, C.W.; Clarke, J.; Genovesi, E.V.; Medina, 
I.; Lamb, L.; Wyde, P.R.; Krystal, M.; Meanwell, N.A. Respiratory syncytial virus fusion 
inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in 
vivo. Bioorg Med Chem Lett. 2006, 16, 1115-22. 
88. Pagani, F.; Sparatore, F. Benzotriazolyl-alkyl-benzimidazoles and their dialkyl-aminoalkyl 
derivatives. Boll. Chim. Farm. 1965, 104, 427-31. 
89. Paglietti, G.; Boido, V.; Sparatore, F.; Substituted benzimidazoles antiviral agents. 
Farmaco-Ed. Sci. 1975, 30, 504. 
90. Tonelli, M.; Paglietti, G.; Boido, V.; Fabio, Sparatore, F.; Marongiu, Fabio; Marongiu, E.; 
La Colla, P.;  Loddo, R.; Antiviral Activity of Benzimidazole Derivatives. I. Antiviral 
Activity of 1-Substituted-2-[(Benzotriazol-1/2-yl)methyl]benzimidazoles). Chem. 
Biodiversity. 2008, 5, 2386-401. 
91. Hosoya, M.; Balzarini, J.; Shigeta, S.; De Clercq, E. Differential Inhibitory Effects of 
Sulfated Polysaccharides and Polymers on the Replication of Various Myxoviruses and 
Retroviruses, Depending on the Composition of the Target Amino Acid Sequences of the 
Viral Envelope Glycoproteins. Antimicrobial agents and chemotherapy. 1991, 35, 2515-
2520. 
92. Watanabe, W.; Sudo, K.; Sata, R.; Kajiyashiki, T.; Konno, K.; Shigeta, S.; Yokota, T.; 
Novel anti-respiratory syncytial(RS) viral compounds: benzodithiin derivatives. 1998, 249, 
922-6. 
 49 
Publications of P. Farci 
Tonelli, M.; Vettoretti, G.; Tasso B.; Novelli, Federica; Boido, V.; Sparatore, F.; Busonera, B.; 
Ouhtit, A.; Farci, P.; Blois, S.; Giliberti, G.; La Colla, P. Acridine derivatives as anti-BVDV 
agents: A preliminary study. Antiviral Research, 2011, 91, 133–141. 
 
Cottiglia, F.; Casu, L.; Leonti, M.; Caboni, P.; Floris, C.; Busonera, B.; Farci, P.; Ouhtit, A.; 
Sanna G. Cytotoxic Phloroglucinols from the Leaves of Myrtus communis. Journal of natural 
products, 2012, 75, 225-229. 
 
Paglietti, G.; Vitale, G.; Corona, P.; Loriga, M.; Carta, A.; Giliberti, G.; Sanna, G.; Farci, P.; 
Marongiu, M.E.; La Colla, P. 5-Acetyl-2 Arylbenzimidazoles and their derivatives as antiviral 
agents. Part 4. European Journal of Medicinal Chemistry (submitted 2011). 
 
 
Abstracts of P. Farci 
 
SIV Congress, 11-14 September 2011, Orvieto (Italy): 
Sanna, G.; Busonera, B.; Giliberti, G.; Farci, P.; Marongiu, M.E.; La Colla, P. Phenyl-
benzotriazoles: new potent and selective inhibitors of Respiratory Syncytial and Hanta viruses. 
 
Congress La Chimica della Vita: da alimenti funzionali a principi attivi, 29-30 September 2011, 
Catanzaro (Italy): 
Cottiglia, F.;  Casu, L.; Leonti, M.; Caboni, P.; Floris, C.; Busonera, B.; Farci, P.; Ouhtit A.; 
Sanna, G. Bioguided-isolation of cytotoxic phloroglucinols from the leaves of myrtus 
communis. 
 
 
